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p53 DRIVES A TRANSCRIPTIONAL PROGRAM THAT ELICITS A NON-CELL
AUTONOMOUS RESPONSE AND ALTERS CELL STATE IN VIVO
Sydney Marie Moyer, B.S.
Advisory Professor: Guillermina Lozano, Ph.D.

Abstract
Cell stress and DNA damage activate the tumor suppressor p53, triggering
transcriptional activation of a myriad of target genes. The molecular, morphological,
and physiological consequences of this activation remain poorly understood in vivo.
We activated a p53 transcriptional program in mice by deletion of Mdm2, a gene which
encodes the major p53 inhibitor. By overlaying tissue-specific RNA-sequencing data
from pancreas, small intestine, ovary, kidney, and heart with existing p53 ChIPsequencing, we identified a large repertoire of tissue-specific p53 genes and a
common p53 transcriptional signature of seven genes which included Mdm2 but not
p21. Global p53 activation caused a metaplastic phenotype in the pancreas that was
missing in mice with acinar-specific p53 activation suggesting non-cell-autonomous
effects. The p53 cellular response at single cell resolution in the intestine altered
transcriptional cell state leading to a new proximal enterocyte population enriched for
genes within oxidative phosphorylation pathways. In addition, a population of active
CD8+ T cells was recruited. Combined, this study provides a comprehensive profile
of the p53 transcriptional response in vivo, revealing both tissue-specific
transcriptomes and a unique signature, which were integrated to induce both cell
autonomous and non-cell-autonomous responses and transcriptional plasticity.
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CHAPTER 1: INTRODUCTION
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1.1 Permission to use previously published works
The introduction is based primarily upon the review article Mdm proteins: critical
regulators of embryogenesis and homeostasis published by Sydney M. Moyer, Connie
A. Larsson, and Guillermina Lozano in the Journal of Molecular Cell Biology on
January 15th, 2017 (doi:10.1093/jmcb/mjx004) (1). The following is from the publisher:
“As part of your copyright agreement with Oxford University Press you have retained
the right, after publication, to use all or part of the article and abstract, in the
preparation of derivative works, extension of the article into a booklength work, in a
thesis/dissertation,

or

in

another

works

collection,

provided

that

a

full

acknowledgement is made to the original publication in the journal. As a result, you
should not require direct permission from Oxford University Press to reuse your article.
Any reuse must comply with the Creative Commons license type your article is
distributed under: http://creativecommons.org/licenses/by-nc/4.0/.”
The remainder of my dissertation is based primarily upon my first-author
manuscript article p53 drives a transcriptional program that elicits a non-cellautonomous response and alters cell state in vivo published by Sydney M. Moyer,
Amanda R. Wasylishen, Yuan Qi, Natalie Fowlkes, Xiaoping Su, and Guillermina
Lozano in the Proceedings of the National Academy of Sciences (PNAS) on
September 10th, 2020 (doi:10.1073/pnas.2008474117) (2). The PNAS website states
the following regarding manuscript permissions and licensing: “For open access
articles submitted beginning September 2017, authors retain copyright, but grant to
PNAS an exclusive License to Publish. Authors and their employing institution or
company retain extensive rights for use of their materials after publication in PNAS
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and for intellectual property. These rights are retained without requiring explicit
permission from PNAS, provided the full journal reference is cited… Users may view,
reproduce, or store journal content, provided that the information is only for their
personal, noncommercial use… Authors retain the following rights under the PNAS
default license: The right to use all or part of their article in a compilation of their own
works, such as collected writings or lecture notes… The right to include the article in
the author’s thesis or dissertation.”
1.2 The p53 transcription factor
The p53 tumor suppressor encodes a transcription factor comprised largely of
two transcriptional activation domains, a core DNA-binding domain, and a
tetramerization domain (3). In response to cell stress, p53 acts as a tetrameric and
sequence-specific DNA binding protein to coordinate a cellular response, primarily
through activation of downstream target genes (3, 4). Initiation of p53 transcriptional
activity is mediated by cell stress such as DNA damage, hypoxia, and oncogenic
signaling (5). p53 activates genes to facilitate distinct cellular outcomes, including but
not limited to: upregulation of cell cycle arrest pathways (via target genes Cdkn1a,
Ccng1), senescence (Cdkn1a), apoptosis (Bbc3, Noxa), or alternations to cell
metabolism (Tigar) (5, 6). Moreover, the importance of p53 is highlighted by the fact
that wild-type p53 function is lost and/or severely dampened in most, if not all, human
cancers (7-9). Specifically, this loss-of-function is most often achieved via missense
mutations within the DNA-binding domain which ablate p53’s ability to interact with the
DNA promoters of its target genes; highlighting transcriptional activation as p53’s
primary tumor-suppressive mechanism (10).
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Activation of specific p53 target genes, out of hundreds suspected to be
regulated by p53, is thought to be largely tissue-specific (11). For example, expression
of the p53 target gene Lif (leukemia inhibitory factor) is required in the uterus of female
mice for proper embryo implantation (12). In fact, decreased Lif levels in p53-/- mice
leads to fewer and smaller litters. Additionally, studies of a hypomorphic mouse model
with slightly elevated p53 levels shows that animals are severely radiosensitive in a
p53-dependent manner (13) and succumb to a sub-lethal dose of radiation in
approximately 20 days. Lethality is caused by bone marrow failure and can be
completely reversed by genetic loss of p53 apoptotic target Puma (Bbc3). Conversely,
loss of cell cycle arrest and senescent p53 target gene p21 (Cdkn1a) was unable to
prolong the life of these mice. These studies implicate the importance of specific p53
genes and pathways in individual tissue types. However, much is still to be learned
about the p53 transcriptome as many phenotypes are observed in mouse models with
elevated p53 that still have not been fully explained (14, 15).
Importantly, pathologies in these hypomorphic mouse models display many
similarities to human diseases that are associated with elevated p53 activity. For
example, CHARGE syndrome is a developmental defect which displays p53associated growth retardation and underdeveloped sex organs (16, 17). Other
diseases, such as Diamond Blackfan Anemia and 5q-syndrome, correlate with p53associated hematopoietic defects and anemia (16, 18, 19). These commonalities
showcase the usefulness of mouse models as a biologically relevant tool for studying
the tissue-specific deleterious effects of elevated p53 activity.
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1.3 Understanding the p53 transcriptome
The major function of p53 is as a transcriptional activator which binds the
proximal promoter regions of the genes which it transcribes (20). To identify the direct
transcriptional targets of p53, multiple groups have conducted ChIP (Chromatin
Immunoprecipitation)-sequencing studies in cell lines with exogenous p53 pathway
activation. For example, Kenzelmann Broz et al. identified over 3,000 gene promoters
with p53 binding sites in mouse embryo fibroblasts (MEFs) treated with the DNAdamaging agent doxorubicin (21). Included in this large set of genes was Cdkn1a
(p21) and Puma, two quintessential p53 target genes, validating the outcomes of the
experiment. Kenzelmann Broz and colleagues also performed pathway analysis of
genes with a p53 binding site within 10 kilobases of the promoter. Through this
analysis they determined that, following DNA-damage, p53 was binding genes
involved in apoptotic regulation, as well as regulation of cell size, blood vessel
development, and cellular adhesion (21).
Li et al. performed a similar study and identified the p53 transcriptional program
in mouse embryonic stem (ES) cells treated with DNA-damaging agent Adriamycin.
This group observed that binding of p53 to promoter regions correlated with gene
activation (22). Specifically, this group found over 3,500 direct p53 target genes
including Cdkn1a and Mdm2. Moreover, Li and colleagues similarly saw enrichment
of genes within cancer-associated and ES cell differentiation pathways (22). While
these invaluable studies provide a pool of potential direct p53 target genes, they were
performed in vitro and lack the cellular complexity of tissues and the physiology of an
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organism. Thus, the biological importance of the target genes identified remains
elusive.

1.4 Mdm2-null and Mdm4-null mice are embryonic lethal
Mdm2 (Murine double minute 2), and its homolog, Mdm4 (also referred to as
MdmX), are two major negative regulators of the tumor suppressor p53 (Figure 1)
(23). Both proteins contain RING finger domains at their respective C-termini. The
RING domain of Mdm2 harbors E3 ligase activity, giving it the ability to initiate p53
degradation, Mdm4 degradation, and degradation of itself (24-26). Although the RING
domain of Mdm4 is not enzymatically active, both Mdm2 and Mdm4 bind the Nterminal transcriptional activation domain of p53 and repress the transcriptional
activity of p53 during homeostasis (27-29). Furthermore, p53 and Mdm2 are involved
in a negative feedback loop; p53 transactivates Mdm2 and Mdm2 in turn targets p53
for proteasomal degradation (Figure 1) (13, 30). Lastly, Mdm2 and Mdm4 form a
heterodimer that maximizes inhibition of p53 (31, 32).
Mdm2-null and Mdm4-null mice are embryonic lethal indicating that Mdm
proteins are vital in development (33-35). Moreover, these phenotypes can be rescued
with concomitant loss of p53 (Mdm2-/-p53-/- and Mdm4-/-p53-/- mice are viable),
indicating that the lethality is due to activation of p53. The loss of Mdm2 in an embryo
results in death due to a p53-mediated apoptotic mechanism (36). This occurs prior
to implantation of the embryos at embryonic day 3.5 (E3.5). In contrast, embryos
lacking Mdm4 initiate cell cycle arrest and occasionally apoptosis, but they do so at
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later developmental timepoints – normally around gastrulation of the embryo (E7.5)
(35, 37).
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Figure 1: Schematic of the Mdm2, Mdm4, and p53 relationships
Mdm2 and Mdm4 are negative regulators of p53. Mdm2 can ubiquitinate p53, itself,
and Mdm4 proteins to target them for proteasomal degradation. p53 binds the Mdm2
promoter initiating transcription in an autoregulatory feedback loop. Mdm2 and Mdm4
can form and function as a heterodimer.
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1.5 Alterations in the intrinsic functions of Mdm2 lead to accumulation and/or
hyperactivity of p53
In attempts to gain a better understanding of the interactions between Mdm2
and p53, multiple mouse models were created which alter the intrinsic functions of
Mdm2 to examine their physiological importance. The Mdm2 gene contains two
promoters; a p53-independent promoter (P1), located upstream from the first exon
that is constitutively active under basal conditions; and a p53-dependent promoter
(P2) residing in the first intron that is only activated in response to DNA damage and
stress conditions (Figure 2A) (30). When DNA is damaged, p53 activates a
transcriptional program that is tumor-suppressive and it has the ability to bind the P2
promoter of Mdm2, which leads to increased Mdm2 levels and subsequent decreased
p53 levels. Pant et al. (2013) generated point mutations in the P2 promoter that disrupt
interactions with p53 (Mdm2P2/P2 mice) to examine the significance of the Mdm2-p53
feedback loop (Figure 2B) (13). While these mice are born at the appropriate
mendelian ratio and abrogation of p53 binding at the Mdm2-P2 promoter does not
alter basal levels of Mdm2 or p53, mice are extremely sensitive to low-dose ionizing
radiation (IR). This lethal phenotype is p53 dependent as deletion of p53 rescues bone
marrow failure. These results signify that elevated p53 levels in mice subjected to DNA
damage have insufficient levels of Mdm2 protein to return p53 to normal levels. The
inability of p53 to upregulate Mdm2 results in extended p53 activity and a p53dependent death.
Another mouse, Mdm2Y487A/Y487A, was generated to specifically examine the
importance of Mdm2 E3 ligase activity (38) (Figure 2B). A point mutation at amino acid

9

487 in the C-terminus of Mdm2 disrupts E3 ligase activity yet allows Mdm2 to inhibit
p53 by binding the transcriptional activation domain and thus results in viable mice.
However, as with Mdm2P2/P2 mice, Mdm2Y487A/Y487A mice are sensitive to IR (38).
Surprisingly, these studies reveal that the E3 ligase function of Mdm2 is dispensable.
These differences in viability also showcase the lower levels of Mdm2 activity required
for homeostasis. Another mouse with a mutation at amino acid 462 of Mdm2 that
disrupts both E3 ligase function and interactions with Mdm4, Mdm2C462A/C462A, is lethal
because of too much p53 activity (39). Thus, inhibition of p53 activity via Mdm2 and/or
Mdm2/Mdm4 heterodimers is critical for cell viability and development.
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Figure 2: Mdm2 form and function
Exons are depicted by black boxes marked with the appropriate number. A: The wildtype Mdm2 allele. P1 and P2 denote Mdm2 promoter regions. The red box in intron
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one represents the p53 response element. The ATG site is within exon 3 of the gene.
B: The wild-type (WT) allele of Mdm2 is shown. The Mdmflox allele creates a
conditionally null allele by flanking exons 7 through 9 with loxP sites. These exons will
be removed after Cre-mediated recombination of the loxP sites. Mdm2FM is generated
using loxP sites surrounding exons 5 and 6, which encode the p53 interaction domain.
The Mdm2puro allele retains a puromycin cassette in intron 6. The PND (mutant P2promoter, neomycin cassette, and 184-bp deletion) allele has a 184-bp deletion in
intron 3 in conjunction with retention of a neomycin cassette and mutation of the p53
response elements. Mdm2-null and Mdm2Δ7-9 are functionally null Mdm2 alleles with
deletion of exons 10-12 and 7-9, respectively. The Mdm2P2 allele harbors mutation of
the p53 binding sequences in the Mdm2 promoter 2, allowing for basal Mdm2
expression. The Mdm2Y487A allele contains a point mutation at amino acid number 487.
This knock-in mutation converts a Tyrosine to an Alanine thus disrupting the E3 ligase
activity of the Mdm2 RING domain but still allowing it to bind to Mdm4. The Mdm2C462A
allele contains a point mutation at amino acid number 462. This knock-in mutation
converts a Cysteine to an Alanine thus removing E3 ligase and disrupting interactions
with Mdm4. The colored bar to the left of the alleles represents relative Mdm2
expression

(red

=

high/normal

expression,

yellow

=

low/no

expression).

Corresponding references and protein expression/function is displayed to the right of
the allele schematics.
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1.5 Alterations in Mdm2 gene dosage drive deleterious p53 activity
Haploinsufficiency (50% of normal expression) of Mdm2 is sufficient to
moderate p53 levels during homeostasis and mice with a single copy of Mdm2 are
developmentally normal and have a normal lifespan. However, Mdm2+/- mice display
increased radiosensitivity due to defects in the hematopoietic system which result in
p53-dependent bone marrow failure following a sub-lethal dose of radiation (40, 41).
In contrast to these relatively normal Mdm2 heterozygous mice, the Mdm2/Mdm4
double heterozygotes (Mdm2+/- Mdm4+/-) show defects in neural tube closure during
development and have multiple organ defects. Furthermore, all blood cells are
depleted in the double heterozygotes though there is no sign of this in single
heterozygotes (Mdm2+/- or Mdm4+/-). Importantly, all double heterozygotes
(Mdm2+/- Mdm4+/-) die within 20 days of birth, signifying the importance of the levels
of these proteins in development and survival. All defects, however, are rescued by
concurrent loss of one allele of p53.
Mendrysa et al. (2003) generated a hypomorphic model of Mdm2, which only
expresses 30% of WT levels (15). This allele, Mdm2puro, contains a puromycin
resistant cassette within the 6th intron (Figure 2B). Mendrysa and colleagues
combined this allele with a functionally null Mdm2 allele which is missing exons 7-9,
Mdm2Δ7-9. These Mdm2puro/Δ7-9 mice are viable with defects in homeostatic tissues.
These mice have smaller body weights accompanied by small organs with those
having the most significant decrease in size being the spleen and thymus. Not
surprisingly, these Mdm2puro/Δ7-9 mice also have a poorly functioning hematopoietic
system. They exhibit significant reduction of red blood cells, white blood cells,
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lymphocytes, T cells, and B cells compared to wild-type animals. Additionally, the
lymphatic system of Mdm2puro/Δ7-9 mice show twice the normal amount of apoptosis
and an increase in p53 transcriptional targets, with p21 experiencing the greatest
upregulation. As expected, these mice also exhibit a p53-dependent increased
sensitivity to radiation.
Recently, another Mdm2 hypomorphic mouse (Mdm2PND/PND) was generated
and identified due to increased pigmentation of its ears, tail, and paws (14). The Mdm2
gene contains two promoters; a p53-independent promoter (P1), located upstream
from the first exon that is constitutively active under basal conditions; and a p53dependent promoter (P2) residing in the first intron that is only activated in response
to DNA damage and stress conditions (Figure 2) (30). The Mdm2PND/PND mouse
harbors a mutation in the P2 promoter in addition to a large deletion in intron 3 and
retains a neomycin cassette. Thus, minimal levels of Mdm2 are being encoded solely
from the P1 promoter. These mice express levels of Mdm2 close to the threshold
needed for survival; Mdm2PND/PND mice are viable whilst Mdm2PND/- mice are not. Pant
et al. (2016) found that Mdm2PND/PND mice have approximately 20% Mdm2 protein
expression compared to wild-type mice, insinuating that between 10-20% Mdm2 is
essential for viability (14).
Further characterization of these mice reveals high basal levels of canonical
p53 targets expressed in spleens that increase upon radiation (IR). Furthermore,
Mdm2PND/PND mice are extremely sensitive to IR and die after exposure to a single 3
gray dose, despite the fact that this exposure is not lethal for wild-type mice. Even
without induced stresses such as IR, these Mdm2PND/PND mice have shorter lifespans
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than wild-type controls (cause of death has not been elucidated), signifying that the
prolonged increase in p53 is harmful.
Further phenotypic defects include weight differences in the Mdm2PND/PND mice
compared to wild-type controls at one year of age. Not only do the Mdm2PND/PND mice
weigh less in general, but they also have disproportionately smaller hearts and
testicles at 6 weeks of age. The small heart phenotype resolves itself by one year of
age at which time they weigh the same as wild-type hearts. The reasons for the
differences in heart weight are unknown but the Mdm2PND/PND mice do not seem to be
negatively affected by the reduced heart weight during development. Despite some
mice being fertile, the litter numbers are lower than expected, and the reproductive
tracts of these mice are significantly smaller throughout their life and contain less germ
cells resulting in breeding difficulties.
Not surprisingly, the hematopoietic system of the Mdm2PND/PND mice is also
altered. Blood count analyses reveal that both white and red blood cell counts in these
mice are significantly lower than the wild-type age and sex-matched controls. The
obvious dark pigmentation in these mice is coupled with spindled melanocytes and
higher than normal melanin content. Furthermore, the pigmentation changes are
specific to the epidermal layer; the dermis is indistinguishable from wild-type. This
signifies clear tissue-specificity of Mdm2 loss and p53 hyperactivity though the
reasons for these phenotypic differences have not yet been determined.
Loss of one copy of p53 is sufficient to dampen the melanin hyperpigmentation
and completely rescues the differences in weight and reproductive tract deficiencies
of the Mdm2PND/PND mice (14). Complete loss of p53 was able to fully restore normal
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skin pigmentation. Moreover, to explore the tissue-specificity of downstream p53
targets p21-null, Puma-null, and p21;Puma-double null mice were crossed with
Mdm2PND/PND mice. p21-loss decreases the severity of testes shrinkage but does not
rescue fertility nor does it alleviate any of the observed ovary defects seen in
Mdm2PND/PND females, suggesting gender differences in sensitivity to hypomorphic
Mdm2. Puma-loss completely rescues all reproductive shortcomings resulting in
normal litter numbers and sizes.
These studies of hypomorphic Mdm2 mouse models beautifully display the
importance of the balance between Mdm2 and p53. As mice have less Mdm2 activity,
p53 transcriptional activity increases to dangerously high levels. Even loss of a single
copy of Mdm2 is unable to tame p53 activity following organismal stress such as IR.
As Mdm2 levels decrease, p53-dependent phenotypes get more severe spanning
multiple tissues such as the hematopoietic system, the heart, and the reproductive
organs. These hypomorphic alleles titrate p53 levels to variant extents and taught us
that somewhere between 10-20% Mdm2 is required for survival, otherwise p53 activity
results in lethality.

1.6 Pathologies upon global Mdm2 loss in adult mice
Since Mdm2 is the major negative regulator of p53, it has become an alluring
therapeutic target for cancers that overexpress Mdm2 and remain wild-type for p53,
such as sarcomas (27%), glioblastomas (10%), and lung adenocarcinomas (~10%)
(9). However, these therapies are not tumor-specific and the adverse effects of these
drugs on normal tissues must be explored. Zhang et al. (2014) addressed this
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question by conditionally removing Mdm2 in a fully developed mouse (2-4 months old)
using a tamoxifen inducible CAG-CreERTg allele to recombine the conditional Mdm2FM
allele in all tissue types (42). Using a single copy of this allele in conjunction with an
Mdm2-null allele (Mdm2FM/- CAG-CreERTg) requires a single recombination event to
generate an Mdm2-null cell, making this model extremely efficient at genetically
ablating Mdm2. Tamoxifen injections were administered once a day for three
consecutive days and all Mdm2FM/- CAG-CreERTg mice in the study died within four
days after the last tamoxifen injection. It is important to note that although all tissues
experience recombination of the Mdm2 allele, the degree of recombination is tissuespecific and does not directly correlate with the severity of the resulting phenotype.
Results indicate that both radio-sensitive and radio-insensitive tissues, such as
the spleen and kidney, respectively, are negatively affected by the loss of Mdm2.
Functional and morphological defects of the Mdm2FM/- CAG-CreERTg mouse vary by
age and tissue type, yet all tissues experience some degree of perturbation of the p53
pathway shown through qRT-PCR analysis of downstream targets. For example, after
global Mdm2 loss, there is an increase in protein casts and tubule dilation in kidneys
of 4-month-old mice, whilst maintaining normal blood urine nitrogen (BUN)
concentration. Normal BUN concentration signifies that the Mdm2FM/- CAG-CreERTg
kidneys are still functioning properly despite significant morphological differences.
Additionally, the kidney harbors the highest levels of p53 target genes, p21 and Puma.
Immunohistochemistry (IHC) reveals that p53 is stabilized in the kidney after Mdm2
loss and apoptosis is evident. Conversely, the Mdm2FM/- CAG-CreERTg liver appears
phenotypically normal compared to control tissues. However, the level of aspartate
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aminotransferase increases substantially, indicating that the livers of these mice are
not functioning properly. Interestingly, the Mdm2FM/- CAG-CreERTg heart has no
obvious morphological defects after acute Mdm2 loss yet still shows significant
increases in the mRNA levels of p53 target genes p21 and Puma. Additionally, IHC
does reveal changes in p53 protein levels. However, after prolonged exposure to p53
activation (through interrupted tamoxifen injections – one injection every other day for
three total tamoxifen injections) fibrosis starts to show up in the heart. Increased
exposure to Mdm2 loss causes stabilized p53 in addition to the morphological defects.
Similarly, another group conducted an analogous study in which they globally
explored p53 reactivation in a Mdm2-null background (43). This study utilizes the
p53KI/- mouse model which contains a p53-ER fusion. In the absence of tamoxifen,
the p53KI allele is functionally null (it should be noted, however, that the p53KI allele
retains minimal p53 function as p53KI/KI mice do not rescue the Mdm2-null phenotype
but p53KI/- mice do). However, upon tamoxifen treatment, the wild-type p53 activity of
this allele is restored. Thus, Mdm2 is never present within these mice, and p53 activity
is being toggled on and off by the presence or absence of tamoxifen injections.
Mdm2-/- p53KI/- mice exhibit similar defects to those found in the Zhang et al. (2014)
study (42). After the reactivation of p53 through daily tamoxifen injections, these
Mdm2-/- p53KI/- mice only survive for up to 6 days. This group found that defects are
seen in radio-sensitive tissues as early as 6 hours after reactivation of WT p53. Not
surprisingly, these Mdm2-/- p53KI/- mice experience dramatic atrophy in radiosensitive tissues such as the bone marrow, spleen (which lacks white pulp), thymus,
small intestine and colon (which have shortened villi). In addition, all these tissues
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show dramatic upregulation in p21 and Puma expression and have numerous
apoptotic cells. These mice also exhibit hematopoietic defects evident by an extreme
reduction in all blood cell types.
Contrary to the Zhang study, radio-insensitive tissues experience fewer defects
when utilizing the p53KI allele. The Mdm2-/- p53KI/- heart, liver, kidney, and brain all
remain morphologically normal with no signs of increased proliferation or apoptosis.
However, all tissues, especially the kidney and the brain, display elevated mRNA
levels of p21 and Puma indicating that they are still affected by reactivation of p53.
This study exemplifies the fact that radio-sensitive and radio-insensitive tissues
are vulnerable to the loss of Mdm2 (Mdm2-/- p53KI/-), and results in the demise of mice
due to unrestricted activity of p53. However, it is important to note that the results from
the p53KI allele are different from the genetic ablation of Mdm2 due to the presence of
only one copy of p53 which must be kept active by continuous tamoxifen injections.
The tissue-specificity of unrestricted p53 activity must be explored further to better
understand the differences observed in these studies.
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CHAPTER 2: AN IN VIVO SIGNATURE OF p53 TRANSCRIPTIONAL ACTIVITY
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2.1 Introduction
To determine the effects of global Mdm2 loss and subsequent p53 activation in
an adult mouse, our laboratory used the conditional Mdm2 allele (Mdm2FM) and a
ubiquitously expressed but tamoxifen-inducible Cre transgene (CAG-CreERTg) to
generate a robust genetic model of p53 activation in C57BL/6J mice (42). Our
experimental groups consisted of Mdm2FM/- CAG-CreERTg (FMTg) mice, which
require only a single recombination event to lose Mdm2 in a cell, along with Mdm2FM/(FM) control mice which retain expression of Mdm2.
In this model, three daily intraperitoneal (IP) tamoxifen injections (1.5mg) to 24 month old FMTg mice induce p53-dependent morbidity on average 4 days after the
last injection. Mice with concomitant loss of p53 (Mdm2FM/- p53-/- CAG-CreERTg) or
no transgene (Mdm2FM/-) showed no signs of morbidity (42). Moribund mice displayed
protein casts in the kidney, villus atrophy in the intestine, and decreased white pulp in
the spleen among other reported phenotypes. However, the p53 target genes
responsible for these phenotypes was not determined.
Similar to published studies by Zhang et al. (42), I utilized the FMTg model to
genetically activate p53 pathway activity. My control cohort consists of Tg mice
(Mdm2+/- CAG-CreERTg) which retain Mdm2 expression but will capture any and all
effects of Cre recombinase expression on the p53 pathway. To gain a better
understanding of how the p53 pathway is driving these detrimental morphological
defects, we captured acute p53 transcriptional activity in the FMTg pancreas,
intestine, ovary, kidney, and heart via RNA-sequencing. Two of these tissues remain
morphologically normal after p53 activation (ovary and heart) while the pancreas,
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intestine, and kidney all show robust phenotypes just 24 hours after p53 activation
(described in detail within this chapter).
We combined our RNA-sequencing data with previously published wild-type
p53 ChIP-sequencing data in order to determine which differentially expressed genes
were direct p53 target genes. Through this analysis, we were able to describe a novel
in vivo signature of wild-type p53 transcriptional activity composed of 7 p53 target
genes: Ccng1, Eda2r, Gtse1, Mdm2, Psrc1, Polk, and Zfp365. We further tested this
signature to show that it is responsive to other forms of p53 activation, specifically
sub-lethal radiation, in a different mouse strain (BALB/c). Additionally, our studies
found that expression of this signature is independent of p53 phosphorylation at
serine-15, the site phosphorylated following radiation (44, 45). These findings are
detailed within this chapter.
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2.2 Methods
Animal Studies
CAG-CreERTg mice were initially purchased from The Jackson Laboratory
(stock no: 004453). Mdm2FM/+ mice were intercrossed to generate Mdm2FM/FM mice.
Mdm2+/- and CAG-CreERTg mice were intercrossed to generate Mdm2+/- CAGCreERTg mice (herein referred to as Tg mice). Mdm2FM/FM and Mdm2+/- mice were
intercrossed to generate Mdm2FM/- mice (herein referred to as FM mice). Mdm2FM/FM
female mice and Tg male mice were intercrossed to generate Mdm2FM/- CAG-CreERTg
mice (herein referred to as FMTg mice). Primers used for genotyping of these mice
are in Table 1. All mice were maintained in a >90% C57BL/6J genetic background.
Genotyping was carried out as described earlier through PCR amplification followed
by resolution on an agarose gel (46, 47).

Tamoxifen treatments
Tamoxifen was purchased from Sigma-Aldrich (catalog number: 10540-29-1).
Tamoxifen was dissolved in corn oil to a final working concentration of 30 mg/mL.
Once dissolved, Tamoxifen was aliquoted into 500µl or 1mL aliquots to avoid freeze
thaw cycles and stored at -20 degrees Celsius for up to 6 months while being
continually protected from light. FM, Tg, and FMTg mice were subject to
intraperitoneal (IP) injections of tamoxifen. For the moribund studies of chronic p53
activity, 2-month-old FM, Tg, and FMTg mice were given 3 daily doses of 1.5mg
(~3mg/40g; 50µl) IP tamoxifen. To capture acute p53 activity, 2-month-old FM, Tg,
and FMTg mice were given a single 3mg (~6mg/40g; 100µl) IP tamoxifen injection.
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Quantitative real-time PCR (qRT-PCR)
RNA was extracted from frozen, pulverized murine tissues using Trizol reagent
(Invitrogen, Carlsbad, CA), and then reverse transcribed using iScript cDNA synthesis
kit (Biorad, Hercules, CA). qRT-PCR was carried out as previously described using
SYBR green (Bimake, Houston, TX) on the CFX384 Touch Real-Time PCR Detection
System (Biorad, Hercules, CA) (48). Expression was normalized to Rplp0 (qRT-PCR
primer sets are located within Table 2).

Protein analysis
Protein lysates were prepared by lysing frozen pulverized tissue in 1x loading
buffer. DNA was sheared using a sonicator and samples were boiled at 95 degrees
Celsius for 10 minutes to denature protein. 25µl was resolved on 10% SDS-PAGE
gels and immunoblotted with antibodies against full-length p53 (FL393, sc06243,
Santa Cruz [dilution 1:500]) and gTubulin (ab11317, Abcam [dilution 1:5000]) or
Vinculin (V9131, Millipore Sigma [dilution 1:5000]) loading controls. Blots were rerun
after normalizing protein concentration to loading controls using ImageJ software
(National Institutes of Health). Western blots were repeated at least three times with
biological replicates.

Histopathology and immunohistochemistry
Tissues harvested from mice were fixed in 10% neutral buffered formalin and
paraffin-embedded. Tissue processing, paraffin embedding, 5 micrometer sectioning,
and hematoxylin and eosin staining were performed by the MD Anderson Department
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of Veterinary Medicine and Surgery Histology Laboratory. Immunohistochemistry was
performed using standard methods with citrate buffer or Tris-EDTA pH 9.0 for 30
minutes of antigen retrieval. Slides were stained with antibodies against cytokeratin
19 (ab133496, Abcam [dilution 1:5000]), cleaved caspase-3 (9664, Cell Signaling
[dilution 1:200]), and gH2AX (MA5-33062, ThermoFisher Scientific [dilution 1:200]).
Visualization was performed using ABC and DAB kits (Vector Laboratories) and
hematoxylin was used as the counterstain. Slides were examined by light microscopy.

RNA-sequencing
RNA was extracted from frozen, pulverized murine tissues using Trizol reagent
(Invitrogen, Carlsbad, CA). Samples submitted for sequencing can be found in Table
5. RNA samples were used to generate a next generation sequencing (NGS) library
composed of random fragments that represent the entire sample. Library preparation
is automated using the Eppendorf EPMotion 5075 or the Agilent Bravo Liquid
Handlers. The library is quantified by qRT-PCR and quality control is validated using
the Agilent TapeStation. The cDNA library was then run with 10 samples per lane on
the Illumina HiSeq4000 platform generating 76bp paired end reads. Reads were
aligned to the GRCm38.p6 using STAR (version 2.6.ob) (49). SAMtools (v1.8) then
sorted reads and calculated mapping statistics (50). The quality of the FASTQ reads
was verified using Program FastQC (0.11.5). GENCODE M19 (Ensembl 94) was
employed for annotation of genes (51). Differentially Expressed Genes were called
using R (3.5.1) and Bioconductor package DESeq2 (52). DESeq2 carried out read
count filtering, normalization, dispersion estimation, and identification of differential

25

expression. DESeq2 modeled the counts using a negative binomial distribution,
followed by the Wald test. The final p-value was adjusted using the Benjamini &
Hochberg method.

Chromatin Immunoprecipitation (ChIP)-PCR
Chromatin immunoprecipitations on FMTg pancreas samples was based on
previously published protocols (53). Briefly, 200mg of flash frozen pancreas tissue
was crushed with liquid nitrogen. Tissue was then subject to formaldehyde crosslinking for 10 minutes with proteinase inhibitors and cross-linking was quenched for 5
minutes by the addition of glycine. Tissues were then Dounce homogenized to obtain
single cells. Cells were resuspended in 750µl of ice-cold immunoprecipitation buffer
(100 mM Tris, pH 8.6; 0.3% SDS; 1.7% Triton X-100; 5 mM EDTA) and sonicated to
an average length of 300 bp (confirmed by agarose gel electrophoresis) by pulsing 40
times for 30 seconds followed by 30 seconds of rest and 50% amplitude on a
sonicator. Immunoprecipitations were performed with approximately 1mg of protein
and conducted in technical triplicates. Antibodies used were p53 (CM5, Leica [0.5µg
per immunoprecipitation]) and Normal Rabbit IgG (2729, Cell Signaling Technology
[0.5µg per immunoprecipitation]). Antibodies incubated overnight at 4 degrees
Celsius. Immunoprecipitations were then incubated for 2 hours with magnetic Protein
G and A Dynabeads (ThermoFisher Scientific, 10001D, 10003D). ChIP washes and
elusions were carried out exactly as previously described (53). qPCR was carried out
as previously described using SYBR green (Bimake, Houston, TX) on the CFX384
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Touch Real-Time PCR Detection System (Biorad, Hercules, CA) (48). ChIP-qPCR
primer sets can be found in Table 3.

Statistical analyses
All data are presented as mean ± standard deviation (SD). All analyses were
performed using GraphPad Prism 8 software. p-value <0.05 were considered
significant. (*) p<0.05, (**) p<0.01 (***) p<0.001. Two groups were compared using a
Students t test and multiple groups were compared using ANOVA with Dunnett’s
correction for multiple comparisons. Survival curve comparisons were made using a
Log-rank Mantel-Cox test.

Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.

Data Availability
RNA-seq data was deposited in National Center for Biotechnology
Information’s Gene Expression Omnibus under accession no: GSE151571. Additional
spreadsheets of analyzed data and ChIP-seq data from Kenzelmann Broz et al., G&D
2013, are available in Dataset 1 of Moyer et al., PNAS 2020 (2, 21).
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Table 1: Primer sets used for genotyping FM, Tg, FMTg, and p53-/- mice, and
recombination of Mdm2FM allele
Primer
Name
Omdm4
Omdm20
Neo3d
FM A
FM B
Cre Tg F
Cre Tg R
Con F
Con R
p53 X6
p53 X7
Neo18.5
Recom F
Recom R
Bactin F
Bactin R

Primer Sequence
ATCTGAGAGCTCGTGCCCTTCG1
TGTGGCTGGAGCATGGGTATTG1
GGCGGAAAGAACCAGCTGGGGC1
TGTGGAGAAACAGTTACTTC2
CTGTGCTCCTTCACAGAG2
GCGGTCTGGCAGTAAAAACTATC3
GTGAAACAGCATTGCTGTCACTT3
CTAGGCCACAGAATTGAAAGATCT3
GTAGGTGGAAATTCTAGCATCATCC3
AGCGTGGTGGTACCTTATGAGC4
GGATGGTGGTATACTCAGAGCC4
TCCTCGTGCTTTACGGTATC4
GAAGCTTGATATCGAATTCCG5
CCGCTCTAGAACTAGTGGAT5
CTGCCTGACGGCCAGGTC
CAAGAAGGAAGGCTGGAAAAGA

Assay
Genotyping: Mdm2- allele
Genotyping: Mdm2FM allele
Genotyping: CAG-CreERTg

Genotyping: p53- allele
Recombination: Mdm2FM
Recombination Control: bactin

The combination of these 3 primers distinguish Mdm2+/+, Mdm2+/-, and Mdm2-/-

1

mouse genotypes. Mdm2+ = ~400 bp PCR product. Mdm2- = 300 bp PCR product.
2

The combination of these 2 primers distinguish Mdm2+/+, Mdm2FM/+, and Mdm2FM/FM

mouse genotypes. Mdm2+ = ~350 bp PCR product. Mdm2FM = ~450 bp PCR product.
3

The combination of these 4 primers will determine the presence or absence of the

CAG-CreERTg allele.
The combination of these 3 primers distinguish between p53+/+, p53+/-, and p53-/-

4

mouse genotypes. p53+ = ~450 bp PCR product. p53- = ~650 bp PCR product.
5

These 2 primers specifically amplify the recombined version of the Mdm2FM allele.
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Table 2: Primer sets used for qRT-PCR assays
Primer
Name
Rplp0 F
Rplp0 R
SP45
SP46
Puma F
Puma R
Ccng1 F
Ccng1 R
Eda2r F
Eda2r R
Gtse1 F
Gtse1 R
Mdm2 F
Mdm2 R
Polk F
Polk R
Psrc1 F
Psrc1 R
Zfp365 F
Zfp365 R

Primer Sequence
CCCTGAAGTGCTCGACATCA
TGCGGACACCCTCCAGAA
CCAGGCCAAGATGGTGTCTT
TGAGAAAGGATCAGCCATTGC
GCGGCGGAGACAAGAAGA
AGTCCCATGAAGAGATTGTACATGAC
TGGCTTTGACACGGAGACATT
GTCCAACACACCCAAGATGC
CACACTGCATAGTCTGCCCTC
GCCTTCTGGACCCGATTGA
AGAGGATCACCAGCAAGCTCCA
GTTTCGTCCTCTGAATGCTGGC
AAGCACCTCACAGATTCCAGC
TTTGCGCTCCAACGGACTT
TCAGCTCGTTAGCTTCCTGTC
GAAGTTGCCTTGCCGTTCC
GAGTGTGCGCTGGAGGTCTAA
GTCCAAGGTCTCGTCCACAAT
CTGAGCCCTGCCACAAAGTA
CGGGATGATGTCCGTTCCAA
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Assay
qRT-PCR: Rplp0
qRT-PCR: p21 (Cdkn1a)
qRT-PCR: Puma (Bbc3)
qRT-PCR: Ccng1
qRT-PCR: Eda2r
qRT-PCR: Gtse1
qRT-PCR: Mdm2
qRT-PCR: Polk
qRT-PCR: Psrc1
qRT-PCR: Zfp365

Table 3: Primer sets used for p53 ChIP-qPCR assays
Primer
Name
Chrm5 F
Chrm5 R
Eda2r F
Eda2r R
Gtse1 F
Gtse1 R
Ccng1 F
Ccng1 R
Mdm2 F
Mdm2 R
Polk F
Polk R
Psrc1 F
Psrc1 R
Zfp365 F
Zfp365 R

Primer Sequence
CCTCCCCCAACTCCACTTTT
GGAGGTTGGAGGGAGAAGGA
CCACACGAAGGATGTTCCCA
GGGTGTCTGCTCTGTACTCG
TTGTGAGGGTCTCCTGTGGT
AATGGGTGGAGTGAGGGACT
GGAACAAGCTGGAGACCTGG
CCACACCAATCAGCGACGTA
AGACGGCTGCGGAAACGG
GCGTCGGCTGTCGGAGGAG
CCTGAGGGTTCTCACGTCC
TTCCGATTCTGCCTTGCGTG
GTCGAGCTTTCTGCACCTTTC
AGAGGCATGGTGGTGGTAAAG
GTGCCAGTCTTGCCCAGCCTA
CACTTTCGCCGCCCCTGC
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Assay
ChIP-qPCR: Chrm5
ChIP-qPCR: Eda2r
ChIP-qPCR: Gtse1
ChIP-qPCR: Ccng1
ChIP-qPCR: Mdm2
ChIP-qPCR: Polk
ChIP-qPCR: Psrc1
ChIP-qPCR: Zfp365

2.3 Results
Loss of Mdm2 in adult mice leads to morbidity and ultimately p53-dependent
lethality 4 days after completion of tamoxifen injections (Figure 3) (42). However, at
the time when mice have become moribund, it is likely that secondary and tertiary
effects of p53 activation have taken place. Thus, we set out to adjust our treatment
regimen to capture the acute p53 transcriptome immediately following Mdm2 loss in
vivo.
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Figure 3: Loss of Mdm2 is lethal in adult mice
A: Treatment regimen for FM (Mdm2FM/-) (n=6, 3 females and 3 males, 60 days of
age), Tg (Mdm2+/- CAG-CreERTg) (n =3 females, 60 days of age) and FMTg
(Mdm2FM/- CAG-CreERTg) mice euthanatized when moribund (n=5, 3 females and 2
males, 60 days old). Time zero is the last day of injections. B: Weight loss at time of
euthanasia as percent of weight on injection day one for FM, Tg, and FMTg mice.
Statistical analysis was conducted with ANOVA utilizing Dunnett’s test for multiple
comparisons against FM mice. C: Kaplan-Meier survival curve for FM, Tg, and FMTg
mice with Log-rank (Mantel-Cox) test for statistical analysis. All data are presented as
mean ± SD from individual mice.
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I generated cohorts of mice with the genotypes Mdm2FM/- (FM), Mdm2+/- CAGCreERTg (Tg), and Mdm2FM/- CAG-CreERTg (FMTg) (Table 1). The Mdm2FM allele has
exons 5 and 6, which encode the p53 binding domain, flanked by loxP sites so that
upon Cre-mediated recombination, these exons are removed and a functionally null
Mdm2 allele is generated (see Chapter 1, Figure 2). The ubiquitously expressed but
tamoxifen-inducible Cre transgene (CAG-CreERTg) allows for temporal control over
recombination of the Mdm2FM allele. The CAG-CreERTg allele is a transgene that
expresses a fusion protein of Cre and a mutated ligand binding domain of the estrogen
receptor; thus, it is only active in the presence of the metabolite of tamoxifen, 4hydroxy-tamoxifen, in a dose dependent manner (54). FMTg mice are heterozygous
for Mdm2 and thus a single recombination event is needed per cell to generate an
Mdm2-null cell. FM and Tg mice retain expression of Mdm2 after tamoxifen injections.
However, both FM and Tg controls were included so that we could determine if Crerecombinase activity alone elicits a biological or p53-specific response in our model.
In attempts to capture the highest amount of Mdm2FM allele recombination and
p53 transcriptional activation (via increased p21 mRNA levels) we performed a dose
finding study on FMTg mice compared to FM and Tg mice. Tamoxifen was
administered via an intraperitoneal (IP) injection. We determined that a single 3mg
dose of tamoxifen followed by sacrifice at 24 hours allowed significant activation of
p53 transcription, as measured by elevated p21 in various tissues, without seeing
strong adverse effects (weight loss) due to Cre activity in the Tg mice (Figure 4A&B)
(Table 2). Thus, we determined that 3mg of IP tamoxifen in just 24 hours was sufficient
to capture the acute p53 transcriptome.
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We next assayed a panel of 13 tissues for p53-transcriptional activity via p21
and Puma expression, and recombination efficiency of the Mdm2FM allele (Tables 1,2,
& 4). Recombination was determined as previously described by Zhang et al (42). We
surprisingly did not observe a significant correlation between percent recombination
and transcriptional activation, suggesting that other cell- and/or tissue-intrinsic
mechanisms regulate the p53 transcriptional program (Pearson correlation; R2=0.13,
two-tailed p-value=0.22). In addition, p21 was always higher than Puma levels except
in the brain and liver (Table 4).
Recombination of the Mdm2FM allele and expression of p21 mRNA in FMTg
tissues generally fell into 4 categories: high Mdm2 recombination, high p21 levels;
high Mdm2 recombination, low p21 levels; low Mdm2 recombination, high p21 levels;
low Mdm2 recombination, low p21 levels. Recombination was considered high if more
than 30% of the tested tissue recombined the Mdm2FM allele. Moreover, if the relative
mRNA level of p21 was greater than 4, the tissue was considered to have high p21
levels. Similar results were also obtained when the expression of Puma was used as
a readout for p53 transcriptional activity (Table 4). To profile the wide-range of p53
activity, we proceeded with five tissues that fell into the four p53-activation groups:
pancreas, small intestine, ovary, kidney, and heart, with two tissues (pancreas and
intestine) represented in the high recombination and high transcriptional activation
group (Figure 4C).
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Table 4: Recombination of the conditional Mdm2 allele, relative p21, and relative
Puma mRNA levels of FMTg compared to Tg mouse tissues 24 hours after 3mg
IP tamoxifen.

Tissue
Pancreas
Heart
Intestine
Liver
Lung
Mammary
Gland
Ovary
Kidney
Brain
Uterus
Bone Marrow
Spleen
Thymus

55.02
53.31
48.16
37.21
35.80

p21 mRNA
Levels
(Fold
Change)
8.37
3.01
4.37
0.23
2.94

Puma mRNA
Levels
(Fold
Change)
3.93
2.02
3.91
1.23
1.67

High p21; High R
Low p21; High R
High p21; High R
Low p21; High R
Low p21; High R

20.18

2.39

1.43

Low p21; Low R

18.97
18.74
18.20
10.10
10.08
8.77
4.65

4.06
7.26
1.27
1.05
1.13
3.54
2.95

2.47
2.40
1.41
0.37
0.33
0.53
0.11

Low p21; Low R
High p21; Low R
Low p21; Low R
Low p21; Low R
Low p21; Low R
Low p21; Low R
Low p21; Low R

Recombination
of Mdm2FM
allele (%)
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Category
R=
Recombination

We

next

conducted

a

more

thorough

molecular

and

histological

characterization of these five tissues. The pancreas, intestine, and kidney of FMTg
mice displayed significant increase of p53 protein compared to Tg tissues, which
correlated well with p21 and Puma mRNA increases (Figure 4D-F). The ovary and
heart, despite efficient recombination of Mdm2, showed a more modest transcriptional
p53 response and lacked robust increases in p53 protein levels. Of note, Tg control
pancreas and heart tissue displayed significant signs of p53 pathway-activation, as
measured by increased p21 mRNA levels and p53 protein levels, compared to Crenegative mice (Figure 5) suggesting that Cre activity induces a stress response. This
phenomenon was most robust in the Tg pancreas.
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Figure 4: Acute p53 activation in Mdm2FM/- CAG-CreERTg mice
A: Treatment regimen and timepoint of euthanasia for Mdm2FM/- CAG-CreERTg mice.
B: Weight loss at euthanasia as a percent of weight on injection day in FM (Mdm2FM/-),
Tg (Mdm2+/- CAG-CreERTg) and FMTg (Mdm2FM/- CAG-CreERTg) mice with Student’s
t test for statistical analysis. C: Correlation between percent recombination of the
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Mdm2FM allele and relative p21 mRNA levels in FMTg mice normalized to Tg mice.
Graph divided into arbitrary quadrants. D: Western blot for p53 protein expression
compared to vinculin (Vinc). Quantification of p53/Vinc signal, relative to Tg sample
within a given tissue type, is indicated below the bands. (P: Pancreas, I: Intestine, O:
Ovary, K: Kidney, H: Heart). E&F: qRT-PCR of tissues from FMTg mice normalized to
Tg mice. Expression normalized to Rplp0. G: Hematoxylin and eosin (H&E) staining.
Yellow lines: crypts. Light green arrows: dilated tubules. Dark green arrows: protein
cast. Yellow arrows: infiltrating immune cells. Scale bar: 100µm. H: Quantification of
crypt loss in intestines of mice 24 hours after tamoxifen. Numbers are total crypts
counted within ten 40x fields and dots indicate biological replicates with Student’s t
test for statistical analysis. I: Number of protein casts per kidney, dots indicate
biological replicates with Student’s t test for statistical analysis. J: Representative
images of Cytokeratin 19 (Ck19) immunohistochemistry and quantification, dots
indicate biological replicates with Student’s t test for statistical analysis. Scale bar:
100µm. K: Quantification of immune cells. Number of immune cells within 5 40x fields;
dots indicate biological replicates. All data are presented as mean ± SD from individual
mice.
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Figure 5: Cre recombinase activity alone activates the p53 pathway
A: Pancreas weight as a percentage of total body weight 24 hours after a single 3mg
tamoxifen injection in FM (Mdm2FM/-), Tg (Mdm2+/- CAG-CreERTg) and FMTg
(Mdm2FM/- CAG-CreERTg) mice. B: qRT-PCR for p21 (top) and Puma (bottom) levels
within the pancreas, heart, ovary, kidney, and intestine. Expression normalized to
Rplp0. C: p53 protein levels in pancreas lysates, g-Tubulin used as loading control. D:
Ingenuity Pathway Analysis for p53 pathway activation from RNA-sequencing data of
the pancreas. Statistical analysis was conducted with ANOVA utilizing Dunnett’s test
for multiple comparisons against FM mice. All data are presented as mean ± SD from
individual mice.
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After only 24 hours, p53 activation resulted in strong morphological changes in
FMTg intestine, kidney, and pancreas compared to Tg mice (Figure 4G). The intestinal
crypts, the invaginated region between the villi that are composed of stem cells and
newly differentiated epithelial cells (55), experienced 20% crypt atrophy/dropout
(Figure 4H). To evaluate apoptosis of crypt epithelial cells, we assayed and quantified
cleaved-caspase-3

positivity

and

accompanying

DNA-damage

(gH2AX

immunohistochemistry) (Figure 6). Throughout FMTg intestines, we could see an
increased number of cells staining positive for apoptosis and DNA damage when
compared to Tg intestines, likely due, in part, to increased p53 activity coupled with
activation of the Cre recombinase (56). In fact, the increase in apoptosis and DNA
damage in FMTg tissues was not unique to the intestine. All tissues, except the heart,
showed marked increases in staining (Figure 6).
Furthermore, following p53 activation, the tubules of FMTg kidneys, structures
crucial for absorption of water and electrolytes (57, 58), were dilated in response to
upregulated p53 (Figure 4G). In addition, large casts of coagulated protein formed
within the kidneys and the overall number of protein casts was significantly higher than
Tg controls (Figure 4G&I). Structural changes to the FMTg pancreatic acinar cells
were reminiscent of acinar to ductal metaplasia and had a 20% increase in area
staining positively with the ductal cell marker cytokeratin 19 (CK19) (Figure 4J).
Additionally, the FMTg pancreas displayed severe necrotizing pancreatitis with robust
immune cell infiltration as evident from hematoxylin and eosin (H&E) staining (Figure
4G&K). Histological analysis revealed that the heart and ovary of FMTg mice did not
display any noticeable morphological differences at this 24-hour timepoint (Figure 4G).
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However, it is important to note that the ovary did show significant increases in staining
for markers of apoptosis and DNA damage while the heart did not (Figure 6).
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Figure 6: Quantification of cell death and DNA damage as a result of p53
activation.
A: Immunohistochemical staining of cleaved caspase 3 for cell death and
corresponding quantification. Scale bar: 100µm. B: Immunohistochemical staining of
gH2AX for DNA double strand breaks and corresponding quantification. Scale bar:
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100µm. Experiments performed in Tg (Mdm2+/- CAG-CreERTg) and FMTg (Mdm2FM/CAG-CreERTg) mice with Student’s t test for statistical analysis. All data are presented
as mean ± SD from individual mice.
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As mentioned previously, FMTg mice with concomitant deletion of p53 display
no signs of morbidity or gross tissue pathologies after IP tamoxifen, demonstrating
that the phenotypes in FMTg mice are p53-dependent (42). Since p53 functions as a
transcription factor, we employed RNA-sequencing to elucidate the transcriptional
programs activated by p53 in FMTg pancreas, heart, kidney, ovary, and intestine
(Table 5). DESeq2 analysis of 5 FMTg compared to 3 Tg tissues revealed hundreds
of genes with an adjusted p-value <0.05 and thus differentially expressed (DE) (Figure
7A and GEO accession no: GSE151571). On average, 85% of all differentially
expressed genes (DEGs) were upregulated in a given tissue; consistent with p53’s
primary function as a positive regulator of transcription (Figure 7A) (59).
To distinguish between direct and indirect transcriptional changes, we
employed previously published ChIP-sequencing data (21). These data were
generated by Kenzelmann Broz et al. from wild-type MEFs that were treated with the
DNA-damaging agent doxorubicin to activate p53 exogenously (21). Overlaying our
tissue-specific RNA-sequencing data with this bulk ChIP-sequencing dataset revealed
the percentage of DEGs identified above that had a p53 binding site (differentially
expressed p53 target genes) (Figure 7B). The kidney and intestine have the largest
percentage of p53-dependent transcriptional changes as the majority of their DEGs
were direct p53 targets (kidney: 59% (77/130); intestine: 69% (42/61)) (Figure 7B). In
addition, these tissues have no downregulated DEGs overlapping with the ChIP-seq
data, suggesting that p53 works exclusively as a transcriptional activator in these
tissues at this time point (Figure 7C). Only 28% (206/747) of the DEGs in FMTg
pancreas were direct p53 target genes and nearly 10% of those targets are
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downregulated (20/206). These data suggest that most of the chances in the pancreas
are indirect (Figure 7C). The heart and ovary, tissues with no robust morphological
phenotype, had the lowest portion of direct p53 target genes differentially expressed
after Mdm2 loss (heart: 16% (95/604); ovary: 24% (21/88)) (Figure 7B).
To understand what particular pathways these tissue-specific p53 target genes
were involved in, we employed Gene Set Enrichment Analysis (GSEA) on Hallmark
and Gene Ontology (GO) pathways (60, 61). Despite presenting different sensitivities
to p53 pathway activation at the morphological level, all five of the tested FMTg tissues
significantly enriched the Hallmark p53 pathway (Figure 7D). Moreover, all five tissues
enriched pathways that share a significant overlap with the Hallmark p53 pathway,
such as response to DNA damage, response to UV, and the GO cell cycle process
pathway. GSEA validated that we successfully captured a p53 response in the murine
pancreas, heart, kidney, ovary, and intestine, and surprisingly that the resulting
differentially expressed gene lists, albeit associated with vastly different tissue-specific
morphological outcomes, activate similar p53-associated pathways.
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Table 5: Comprehensive list of all tissues submitted for RNA-sequencing
#

Mouse #

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

2445
2495
2046
2045
2598
2808
2933
2972
2039
2043
2235
2806
2445
2495
1975
1979
2598
2808
2933
2972
1977
1964
2235
2806
2445
2495
2044
2084
2598
2808
2933
2972
2041
2119
2235
2806
2445
2495
1975
1979

Tissue
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Intestine
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Heart
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Ovary
Kidney
Kidney
Kidney
Kidney

Sex

Genotype

F
F
M
M
F
F
F
F
M
M
F
F
F
F
M
M
F
F
F
F
M
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
M
M

FM
FM
FM
FM
Tg
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
Tg
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
Tg
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
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# Uniquely
RIN
Mapped
Reads
8.2 37450030
8.7 32647019
5.3 49789138
6.7 64402360
9.7 32128301
7.8 28841829
9.0 27806650
8.9 29700059
4.6 35899685
5.3 42999763
9.5 35561988
9.1 27744176
7.4 34221056
6.8 34279953
7.5 51032644
8.3 37729322
8.9 31015098
6.3 31915083
7.2 31273866
8.6 32448579
7.8 37729322
7.6 45181871
7.8 36660807
7.4 32683527
7.4 34357283
7.9 24746382
7.6 37546363
7.7 43129691
6.5 24105815
9.1 31088281
9.2 29365441
8.9 29736737
8.0 37656486
8.5 47897059
9.0 34589206
9.2 28910616
9.1 35310762
9.5 34913233
7.1 48627590
7.1 36530231

Moyer et al.,
2020 PNAS
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85

2598
2808
2933
2972
1977
1964
2235
2806
2445
2495
2045
2046
2598
2808
2933
2972
2039
2043
2971
2806
2044
2046
2045
2084
2891
2934
2047
1964
2119
2041
2044
2084
2046
2045
2934
2891
2119
2041
1964
2047
2044
2901
1980
2598
2808

Kidney
Kidney
Kidney
Kidney
Kidney
Kidney
Kidney
Kidney
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Pancreas
Thymus
Thymus
Thymus
Thymus
Thymus
Thymus
Thymus
Thymus
Thymus
Thymus
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Spleen
Liver
Liver
Liver
Liver
Liver

F
F
F
F
M
M
F
F
F
F
M
M
F
F
F
F
M
M
M
F
F
M
F
F
M
M
M
M
F
F
F
F
M
F
M
M
F
F
M
M
F
M
F
F
F

Tg
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
Tg
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
FM
Tg
Tg
FMTg
FMTg
FMTg
FMTg
FM
FM
FM
Tg
Tg
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9.2
8.6
8.9
9.0
7.5
5.8
9.1
9.3
6.2
6.6
2.5
2.6
6.5
6.9
6.3
6.5
3.8
3.4
6.1
5.7
9.0
9.4
9.6
9.6
9.6
9.4
9.6
9.4
9.7
9.3
8.8
8.6
6.5
7.8
9.6
9.2
9.0
9.3
6.9
7.7
8.8
8.0
7.9
6.3
9.1

30816162
30489923
32318668
27259539
47901729
39915041
41352651
31159655
24869653
21270871
15632223
11415817
21486037
21743073
19363016
21916481
13460153
22805234
26691830
23054880
37890958
16406476
31490124
26592197
19464945
36950036
24179009
33638088
24165840
30653297
21195555
27459361
26795446
27080200
19184827
24768780
29998035
23790222
23079746
23481347
29421565
21160681
27165857
32055284
35427338

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No

86
87
88
89
90

2933
2043
2041
2904
2972

Liver
Liver
Liver
Liver
Liver

F
M
F
M
F

Tg
FMTg
FMTg
FMTg
FMTg
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8.6
8.7
8.8
9.1
8.7

27920732
35422963
37471806
38598676
33357357

No
No
No
No
No
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Figure 7: RNA and ChIP-sequencing data reveals acute p53 transcriptional
response
A: Table depicting the total number of differentially expressed genes (DEGs) that
resulted from DESeq2 analysis of bulk RNA-sequencing data of five tissues after p53
activation. DEGs have a p-value <0.05. B: bar graph depicting the percentage of total
DEGs per tissue that have a p53 binding site (BS) as per Kenzelmann Broz et al.
ChIP-sequencing data (21). These genes are henceforth referred to as differentially
expressed p53 target genes C: Pie graphs depicting the percentage of upregulated
and downregulated differentially expressed p53 target genes (TG) for each tissue. D:
Top 10 enriched pathways from Gene Set Enrichment (GSEA) analysis of Hallmark
and Gene Ontology (GO) pathways for differentially expressed p53 target genes in
FMTg. Red bar highlights Hallmark p53 Pathway in each dataset.
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When combining the data sets from all five of our sequenced tissues we
discovered that only seven DEGs were commonly expressed: Ccng1, Eda2r, Gtse1,
Mdm2, Polk, Psrc1, and Zfp365 (Figure 8A&B). Surprisingly, this list does not include
p21, the gene historically used as the gold-standard readout for p53 transcriptional
activation. However, p21 was significantly differentially expressed in FMTg pancreas,
intestine, and kidney (the tissues with the most robust histological changes).
Importantly, Mdm2 was identified as one of the common differentially expressed target
genes. Deletion of Mdm2 occurs in exons 5-6 leaving an intact p53 binding sequence
in the promoter (Figure 2) (47). The other common differentially expressed genes have
also been previously linked to p53 activity. Eda2r is previously reported to be an
anoikis target for p53 (62). Gtse1 and Psrc1 are paralogs involved in p53 cell-cycle
regulation along with Cyclin G1 (Ccng1) (63-66). Polk is the gene that encodes DNA
Polymerase Kappa which allows for DNA replication in the presence of DNA lesions;
DNA double strand breaks were observed in all tissues and quantified by gH2AX
staining as indicated above (Figure 6) (67, 68). Finally, Zfp365 is a zinc-finger protein
required for proper resolution of DNA double strand breaks (69).
ChIP-qPCR experiments of FMTg pancreas validated binding of p53 at the
promoters of six genes in p53 antibody ChIPs compared to IgG antibody ChIPs
(Figure 8C) (Table 3). Cyclin G1 id likely also significant but was variable in this small
dataset. Additionally, the binding of these genes was enriched over p53 binding at the
Chrm5 promoter; Chrm5 encodes acetylcholine receptor and is not bound by p53 and
thus serves as a negative control for this assay (53). Thus, the functions of these
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seven genes embody the pathways found via GSEA and have been experimentally
validated as p53 target genes through ChIP-qPCR.
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Figure 8: Activation of p53 upregulates a p53 signature
A: Venn diagram, generated using InteractiVenn, overlaying the differentially
expressed p53 target genes for each tissue (70). B: Log2-Fold Change values for the
seven overlapping p53 target genes in A. C: ChIP-qPCR for FMTg (Mdm2FM/- CAGCreERTg) pancreas (n=4) of seven overlapping p53 target genes presented as p53
ChIP/IgG ChIP. Chrm5 encodes an acetylcholine receptor that serves as a negative
control for p53 binding. Student’s t test was used for statistical analysis.
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To determine if these seven genes could serve as a signature for wild-type p53
transcriptional activation in other settings, we exogenously activated p53 by utilizing
radiation (IR) to induce DNA damage (71). A sublethal dose (6 gray) of IR was
administered to both wild-type (n=3) and p53-/- (n=5) BALB/c mice while un-irradiated
wild-type BALB/c mice (n=2) served as controls. All mice were euthanized four hours
after IR exposure when p53 protein is highest (13).
All seven genes showed robust transcriptional activation after IR, in a p53dependent manner, with the kidney showing, consistently, the highest activation of all
seven genes after IR (Figure 9A) (Tables 2&6). Additionally, the use of p53-null mice
allowed us to determine if other transcription factors can activate expression of these
genes post-IR. In fact, there was upregulation of Gtse1 in 3 of 5 irradiated p53-null
pancreas samples. However, this phenomenon did not occur in other tissues (Figure
10).
Following IR, all five tissues tested showed increases in p53 protein levels, with
the intestine and ovary having the highest levels (5.7x and 5.6x, respectively) and
heart, the lowest (1.6x) (Figure 9B). To directly compare p53 protein levels elevated
in response to Mdm2 loss or IR we performed a western blot for total p53 protein in
the kidneys (Figure 9C). The kidneys are of particular interest since they had the
highest induction of our p53-dependent gene signature. Furthermore, in our FMTg
model, the kidney displayed robust tubule dilation and protein cast formation despite
having “low” recombination of Mdm2. Loss of Mdm2 in the kidney increased p53
protein to considerably higher levels (average 4x) than that of IR (average 2x) (Figure
9C). Since p53 is highly post-translationally modified following cell stress such as the
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DNA damage induced by IR (44, 45), we speculated that phosphorylation of p53 may
differ in the kidney after Mdm2 loss compared to IR. We observed significant
phosphorylation of p53 at serine-15 only in irradiated kidney samples (average 4x)
(Figure 9C). Further studies are needed in other tissues to understand the intricacies
of p53 posttranslational modifications and how this affects p53 transcriptional activity.
However, the fact that seven genes (Ccng1, Eda2r, Gtse1, Mdm2, Polk, Psrc1, and
Zfp365) are transcriptionally upregulated in multiple tissues of two different mouse
strains (C57BL6/J and BALB/c) and in response to p53 activation genetically and
exogenously, we propose that they serve as a universal signature for transcriptional
activation by wild-type p53.
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Figure 9: Exogenous activation of p53 through gamma-radiation
A: qRT-PCR of irradiated (IR) wild-type (WT) (n=3) and p53-null (n=5) pancreas,
heart, kidney, ovary, and intestine compared to un-irradiated wild-type (WT) (n=2) for
seven overlapping p53 target genes. Expression normalized to Rplp0. Statistical
analysis was conducted with ANOVA utilizing Dunnett’s test for multiple comparisons
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against irradiated WT mice. All data are presented as mean ± SD from individual mice.
B: Western blot for p53 protein expression compared to vinculin (Vcl). Asterisk (*)
indicates non-specific band. Quantification of p53/Vcl signal, relative to WT sample
within a given tissue type, is indicated below the bands. (P: Pancreas, I: Intestine, O:
Ovary, K: Kidney, H: Heart). C: Western blot for p53 and phosphorylated p53 at serine
15 (p-p53 ser15) and vinculin. Quantification of p53 or p-p53/Vcl signal, relative to first
Tg sample, is indicated below the bands and graphed to the right with Student’s t test
for statistical analysis.
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Figure 10: Gtse1 expression levels after gamma-radiation in vivo
A: qRT-PCR of irradiated (IR) wild-type (WT) (n=3) and p53-null (n=5) pancreas,
heart, ovary, kidney, and intestine from female mice compared to un-irradiated wildtype (WT) (n=2) female mice for Gtse1. Expression normalized to Rplp0. Statistical
analysis was conducted with ANOVA utilizing Dunnett’s test for multiple comparisons
against irradiated WT mice. All data are presented as mean ± SD from individual mice.
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Table 6: Log2-Fold Change values of FMTg compared to Tg tissues for the
proposed p53 signature
Log2-Fold Change values of FMTg compared to Tg tissues for the proposed p53
signature as determined by RNA-sequencing experiments (Heart, Intestine, Kidney,
Ovary, and Pancreas) or qRT-PCR (Bone Marrow, Brain, Liver, Lung, Mammary
Gland, Spleen, Thymus, and Uterus). Values in bold are statistically significant (p <
0.05).
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CHAPTER 3: THE PANCREATIC RESPONSE TO p53 ACTIVATION IN FMTg
MICE IS NON-CELL-AUTONOMOUS
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3.1 Introduction
The FMTg (Mdm2FM/- CAG-CreERTg) pancreas showed a large infiltration of
immune cells (Figure 4G) and a metaplastic phenotype that is caused by inflammation
(72). This, in combination with the small number of direct p53 targets in our RNA-seq
data, led us to hypothesize that the pancreas was responding to ubiquitous organismal
stress from p53 activation and that these morphologic changes were not due to p53
activation in the pancreas specifically.
To address this in a cell-specific manner, we crossed Mdm2FM/- mice to the
tamoxifen-inducible and acinar cell-specific Mist1CreERT2 to generate a small cohort of
FMMist mice (Mdm2FM/- Mist1CreERT2) and Mist controls (Mdm2+/- Mist1CreERT2) (73).
While Mist mice retain expression of Mdm2, FMMist mice recombine the Mdm2FM
allele specifically within the pancreatic acinar cells. An acinar-specific Cre was used
because acinar cells transdifferentiate into ductal cells upon stress resulting in a
metaplastic phenotype (72).
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3.2 Methods
Animal Studies
Mist1CreERT2 mice were purchased from The Jackson Laboratory (stock no:
029228) (73). Mist1CreERT2 mice and Mdm2FM/+ mice were intercrossed to generate
double homozygous, Mdm2FM/FM Mist1CreERT2/CreERT2 mice. Double homozygous males
were then crossed to Mdm2+/- female mice to generate Mdm2FM/- Mist1CreERT2/+
(FMMist) mice. Mist1CreERT2/CreERT2 male mice were also crossed to Mdm2+/- female
mice to generate Mdm2+/- Mist1CreERT2/+ control (Mist) mice. All mice were maintained
in a >90% C57BL/6J genetic background. Genotyping was carried out as described
earlier through PCR amplification followed by resolution on an agarose gel (46). Tg
and FMTg alleles were described in chapter 2.

Tamoxifen treatments
Tamoxifen was purchased from Sigma-Aldrich. Tamoxifen was dissolved in
corn oil to be a final working concentration of 30 mg/mL. Once dissolved, Tamoxifen
was aliquoted into 500µl or 1mL aliquots to avoid freeze thaw cycles and stored at 20° Celsius for up to 6 months while being continually protected from light. FMMist
and Mist mice were subject to intraperitoneal (IP) injections of tamoxifen. FMMist and
Mist mice were given 4 daily doses of 1.5mg (~3mg/40g; 50µl) IP tamoxifen. The Tg
and FMTg injection regimen was described in chapter 2.
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Statistical analyses
All data are presented as mean ± standard deviation (SD). All analyses were
performed using GraphPad Prism 8 software. p-value <0.05 were considered
significant. (*) p<0.05, (**) p<0.01 (***) p<0.001. Two groups were compared using a
Students t test and multiple groups were compared using ANOVA with Dunnett’s
correction for multiple comparisons.

Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.
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Table 7: Primer sets used for genotyping Mist1CreERT2 allele
Primer
Primer Sequence
Assay
Name
MCre 1
GGTTTAAGCAAATTGTCAAGTACGG1
Genotyping: Mist1CreERT2
MCre 2
ATAGTAAGTATGGTGGCGGTCAGCG1
allele
MCre-ER GAAGCATTTTCCAGGTATGCTCAG1
1

The combination of these 3 primers distinguish between Mist1+/+, Mist1CreERT2/+, and

Mist1CreERT2/CreERT2 mice. Mist1+ = ~700 bp PCR product. Mist1CreERT2 = ~500 bp PCR
product.
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3.3 Results
A small time course study was conducted to determine the tamoxifen dosing
regimen necessary to achieve Mdm2 recombination with the Mist1CreERT2 allele that
was comparable to that obtained with the CAG-CreERTg allele. One week after 4 daily
1.5mg IP tamoxifen injections, analysis of the FMMist (Mdm2FM/- Mist1CreERT2)
pancreas showed recombination of the Mdm2FM allele in approximately 55% of cells,
similar to that achieved in the FMTg (Mdm2FM/- CAG-CreERTg) pancreas 24 hours
after a 3mg tamoxifen injection (Figure 11A-B) (Table 1 & 7). To check for p53
transcriptional activity, we evaluated two genes that were amongst the highest
significantly differentially expressed genes in FMTg pancreas RNA-seq data, Eda2r
and Gtse1 (Figure 8B) (Table 2). In fact, qRT-PCR experiments showed induction of
Eda2r and Gtse1 mRNA levels were similar in FMMist and FMTg pancreas samples
(Figure 11C). Moreover, induction of all seven genes in our proposed signature was
observed in FMMist compared to Mist (Mdm2+/- Mist1CreERT2) pancreases (Figure 12)
(Table 2).
Despite comparable recombination and significant p53 transcriptional
activation, FMMist pancreas looked morphologically normal and displayed no signs of
immune cell infiltration or metaplasia compared to Mist controls (Figure 11D&E). The
use of this acinar cell-specific Cre indicated that the robust morphological alterations
seen in FMTg pancreas were influenced by the global activation of p53 throughout the
tissue and/or entire organism and were non-cell-autonomous.
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Figure 11: The pancreatic response to p53 activation in FMTg mice is non-cellautonomous
A: Treatment regimen and timepoint of euthanasia for FMMist (Mdm2FM/- Mist1CreERT2)
and Mist (Mdm2+/- Mist1CreERT2) mice. B: Percent recombination of the conditional
Mdm2FM allele as determined via qRT-PCR assay in Mist, Tg (Mdm2+/- CAGCreERTg), FMMist, and FMTg (Mdm2FM/- CAG-CreERTg) mice. Statistical analysis was
conducted with ANOVA utilizing Dunnett’s test for multiple comparisons against Tg
mice. C: qRT-PCR for relative Eda2r and Gtse1 mRNA levels within the pancreas of
Mist, Tg, FMMist, and FMTg mice. Expression normalized to Rplp0. Statistical
analysis was conducted with ANOVA utilizing Dunnett’s test for multiple comparisons
against Tg mice. D: Hematoxylin and eosin (H&E) staining on pancreas samples.
Scale bar: 100µm. E: Quantification of immune cells. Number of immune cells within
five 40x fields, dots indicate biological replicates with a Student’s t test for statistical
analysis. All data are presented as mean ± SD from individual mice.
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Figure 12: Activation of proposed p53 signature in Mdm2FM/- Mist1CreERT2
pancreases
qRT-PCR of seven genes in proposed signature performed on FMMist (Mdm2FM/Mist1CreERT2) (n=5) and Mist (Mdm2+/- Mist1CreERT2) (n=5) pancreases. Expression
normalized to Rplp0 with Student’s t test for statistical analysis. All data are presented
as mean ± SD from individual mice.
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CHAPTER 4: THE p53 TRANSCRIPTIONAL PROGRAM ALTERS
TRANSCRIPTIONAL CELL STATE IN THE INTESTINE
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4.1 Introduction
To determine how p53 activation can affect individual cell populations we
employed single-cell RNA sequencing to evaluate the p53 transcriptome at cellular
resolution. The intestine of mice that have lost Mdm2 displayed the highest proportion
of p53 transcriptional targets. The intestine is a highly proliferative tissue that
recombined the Mdm2FM allele in ~50% of cells which resulted in significant crypt
dropout, induced cell death, increased DNA damage, and increased p53 protein levels
and transcriptional activity (Figure 4). Additionally, ~70% of DEGs in the intestine have
p53 binding sites (Figure 7B) and thus, the intestine was the best tissue in our model
to use for single-cell RNA-sequencing (scRNA-seq) analysis to determine how
different cell types and cell states were affected by acute p53 activation.
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4.2 Methods
Single-cell RNA-sequencing analysis
Murine small intestines were isolated and rinsed with cold sterile 1X phosphatebuffered saline (PBS). Dissociation of single cells was carried out as previously
described (74). Following single cell dissociation, samples were transferred to The
University of Texas MD Anderson Cancer Center CPRIT SINGLE CORE single cell
sequencing facility which utilizes the 10X Chromium Controller from 10X Genomics.
10,000 FMTg and 10,000 Tg small intestine cells were put through the 10X genomics
pipeline. Libraries were sequenced on Illumina NovaSeq 6000 at The University of
Texas MD Anderson Cancer Center Advanced Technology Genomics Core (ATGC).
Raw sequencing data was then returned to the SINGLE CORE for demultiplexing, alignment, and unique molecular identifier collapsing using the
Cellranger toolkit from 10X Genomics. Data was then returned to our lab where I used
the Seurat (V3.0) R toolkit for single cell genomics analysis to perform quality control,
analysis, and evaluation of our single cell datasets as previously described (75-77).
Cells were excluded if they had less than 200 features or more than 30% mitochondrial
gene contamination. Using the Jackstraw R package, we identified 8 significant
principal components and scores from these components were used for input in
downstream analyses. Visualization was performed using the UMAP function in the
Seurat (V3.0) R package. Basic R code can be found in Appendix A.
Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.
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Data Availability
scRNA-seq data was deposited in National Center for Biotechnology
Information’s Gene Expression Omnibus (GEO) under accession no: GSE152587.
Additional spreadsheets of analyzed data are available in Dataset 1 of Moyer et al.,
PNAS 2020 (2).
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4.3 Results
To determine how p53 is affecting the cell populations within the intestine we
used our FMTg (Mdm2FM/- CAG-CreERTg) model of genetic p53 pathway activation,
compared to Tg (Mdm2+/- CAG-CreERTg) controls, 24 hours after a single 3mg
tamoxifen injection. scRNA-seq on one male FMTg and one male Tg intestine sample
resulted in ~3,000 cells for each group that passed quality control (Figure 13Ai) (GEO
accession no: GSE152587). Using the R-package Seurat, cells were clustered into 13
transcriptionally distinct cell populations capturing both immune and intestinal celltypes based on previously published cell-type specific gene markers (Figure 13Aii-iii
& Figure 14) (75-79). I chose some select gene markers to highlight in Figure 14.
These violin plots show which clusters are composed of cells expressing a given gene
marker, allowing us to determine what cell population each cluster represents. For
example, in Figure 14I, Cd8a is expressed predominately in clusters 0, 2, and 10. This
gene is an established CD8+ T cell marker and thus identifies the specific clusters that
represent this cell type (80, 81). When identifying individual clusters, we used at least
three established gene markers for each cluster. However, one gene marker per
cluster is shown in Figure 14.
The portion of goblet (~66% less cells), paneth (clusters with goblet cells), tuft
(~90% less cells), and distal enterocytes (~50% less cells) was markedly decreased
after p53 activation, consistent with the high amount of quantifiable cell death in this
tissue (Figure 13B & Figure 6). Additionally, the memory CD4+ T cell population was
decreased by ~66% in FMTg mice compared to Tg. The total number of enterocytes
(~600) and T cells (~1500) was similar in both intestinal samples but interestingly,
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there was a proximal enterocyte cell population (proximal enterocytes 2) and CD8+ T
cell population (CD8+ T cells 2) that were enriched in FMTg intestines (Figure 13C-D)
(proximal enterocytes 2: ~50 cells in Tg and ~400 cells in FMTg, CD8+ T cells 2: ~
400 in Tg and ~600 in FMTg).
By extracting the top 100 genes that distinguish these clusters from neighboring
clusters, we were able to run GSEA to see what Hallmark and/or GO pathways were
subsequently enriched due to p53 activation. The top 10 pathways from this analysis
show that this population of proximal enterocytes in FMTg intestines are transcribing
genes associated with oxidative phosphorylation (Figure 13E). In fact, GSEA shows
several pathways in this enterocyte population that are associated with mitochondria
and metabolism, suggesting that this population of proximal enterocytes may be more
metabolically active.
Additionally, the CD8+ T cell population that was prominently displayed in the
FMTg intestine had only 56 significant genes that distinguished it from other T cell
populations. GSEA on these 56 genes identified multiple pathways enriched that
signified this population of T cells were “active” compared to the other T cell clusters
(Figure 13F). The active CD8+ T cell population was likely recruited to the intestine
due to the high p53-induced cell death in this organ. These cell state changes were
dependent on p53 pathway activation as the Tg intestine sample had significantly
fewer cells contributing to these populations and all other cell populations were similar
between FMTg and Tg intestine (Figure 13Aiii).
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Figure 13: Single-cell RNA-sequencing in FMTg intestines provides insight into
cell-state specificity driven by p53 activation
A: (i.) Total number of cells analyzed after quality control metrics ran with Seurat V3
for one FMTg (Mdm2FM/- CAG-CreERTg) and one Tg (Mdm2+/- CAG-CreERTg)
intestine sample, (ii.) UMAP of labeled cell populations (iii.) portion of specific cell
populations in FMTg and Tg samples. B: Total number of goblet and paneth, tuft, distal
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enterocytes, and memory CD4+ T cells in FMTg and Tg intestines. C: Total number
of all enterocytes and T cells per group. D: Number of cells that encompass proximal
enterocyte population 2 and CD8+ T cell population 2 in each intestine sample. E:
GSEA analysis on defining features for proximal enterocyte population 2. F: GSEA
analysis on defining features for CD8+ T cell group 2.
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Figure 14: Single-cell cell-type expression markers for intestine samples
A: UMAP of FMTg (Mdm2FM/− CAG-CreERTg) and Tg (Mdm2+/− CAG-CreERTg) singlecell intestine samples with clusters labeled. B: Proximal enterocyte specific marker.
C: Distal enterocyte specific marker. D: Goblet cell specific marker. E: Tuft cell specific
marker. F: Stem cell specific marker. G: Naïve CD4+ T cell specific Marker. H: Memory
CD4+ T cell specific marker. I: CD8+ T cell specific marker. J: B cell specific marker.
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CHAPTER 5: NOVEL Eda2r KNOCKOUT MICE DISPLAY ROBUST LIVER
VACUOLIZATION WHICH IS ASSOCIATED WITH p53 TRANSCRIPTIONAL
ACTIVATION
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5.1 Introduction
Our study, and others, have identified Eda2r (Ectodysplasin A2 Receptor, also
known as XEDAR, EDA-A2 Receptor, and TNFRSF27) as a downstream
transcriptional target of p53 in multiple cell types (2, 21, 62, 82). To further elucidate
the role that this gene plays in the p53 pathway, I generated germline Eda2r knockout
mice.
Briefly, Eda2r is located on the reverse strand of the murine X-chromosome.
The murine Eda2r transcript is 43,369 base pairs spanning 8 exons. Eda2r encodes
a 297 amino acid transmembrane receptor protein belonging to the tumor necrosis
factor receptor superfamily (83). In vitro studies suggest that Eda2r is an anoikis target
of p53 and can induce caspase-dependent apoptosis (62, 84, 85). However, these
studies are extremely limited. Additional in vivo studies are needed to elucidate the
role of Eda2r within the p53 pathway.
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5.2 Methods
Gene targeting strategy
The ATG start codon is located within exon 3 of Eda2r. The entire sequence of
exon 3 was used to score possible target sites on the crispr.mit.edu webtool. Two
guides with high scores were chosen to pursue in vivo targeting (guide #1:
GAATGAGTACCGGGACCAATGGG

forward

strand

[score:

86];

guide

#2:

CACAGCGCCCCCATTGGTCCCGG reverse strand [score: 85]). CRISPR (Clustered
Regulatory Interspaced Short Palindromic Repeats) sgRNA kits were purchased from
Synthego for each guide. The pronuclei of wild-type C57BL/6J zygotes were then
injected or electroporated with the sgRNA and Cas9 mRNA and then implanted into
pseudo-pregnant female mice ([Injection (guides injected concurrently): sgRNA1: 400
nM, sgRNA2: 400 nM, Cas9 protein (Sigma, Enhanced specificity): 200 nM, dilution
buffer: 10 mM Tris pH 7.4, 0.1 mM EDTA] [Electroporation (guides electroporated
separately): sgRNA: 4 µM, Cas9 protein (Sigma, Enhanced specificity): 4 µM, dilution
buffer: Gibco Opti-mem [Thermo Fischer]). All injections and electroporation of
zygotes as well as implantation was performed by the MD Anderson Cancer Center
Genetically Engineered Mouse Facility (GEMF).

Animal Studies
Generation of Eda2rΔ11 mice is described in detail within this chapter.
Generation of these mice was performed in collaboration with the GEMF. Wildtype
C57BL/6J and Alb-CreTg mice were initially purchased from the Jackson Laboratory
(stock nos: 000664 and 003574, respectively). Mdm2FM/+ mice were intercrossed to
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generate Mdm2FM/FM mice. Mdm2FM/- and Alb-CreTg mice were intercrossed to
generate Mdm2FM/- Alb-CreTg and Mdm2FM/FM Alb-CreTg mice (herein referred to as
FMAlb mice). All mice were maintained in a >90% C57BL/6J genetic background.
Genotyping was carried out as described earlier through PCR amplification followed
by resolution on an agarose gel (46).

Histopathology and immunohistochemistry
Tissues harvested from mice were fixed in 10% neutral buffered formalin and
paraffin-embedded. Tissue processing, paraffin embedding, 5 micrometer sectioning,
and hematoxylin and eosin staining were performed by the MD Anderson Department
of Veterinary Medicine and Surgery Histology Laboratory. Immunohistochemistry was
performed using standard methods with citrate buffer or Tris-EDTA pH 9.0 for 30
minutes of antigen retrieval. Slides were stained with antibodies against p53 (CM5,
P53-CM5P-L, Leica Biosystems [dilution 1:200]). Visualization was performed using
ABC and DAB kits (Vector Laboratories) and hematoxylin was used as the
counterstain. Slides were examined by light microscopy.

Quantitative real-time PCR (qRT-PCR)
RNA was extracted from frozen, pulverized murine tissues using Trizol reagent
(Invitrogen, Carlsbad, CA), and then reverse transcribed using iScript cDNA synthesis
kit (Biorad, Hercules, CA). qRT-PCR was carried out as previously described using
SYBR green (Bimake, Houston, TX) on the CFX384 Touch Real-Time PCR Detection
System (Biorad, Hercules, CA) (48). Expression was normalized to Rplp0.
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Statistical analyses
All data are presented as mean ± standard deviation (SD). All analyses were
performed using GraphPad Prism 8 software. p-value <0.05 were considered
significant. (*) p<0.05, (**) p<0.01 (***) p<0.001. Two groups were compared using a
Students t test and multiple groups were compared using ANOVA with Dunnett’s
correction for multiple comparisons.

Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.
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Table 8: Primer sets used for Sanger sequencing of Eda2r knockout mice and
routine genotyping of the Eda2rΔ11 and Alb-CreTg alleles.
Primer
Name
Eda2r 363F
Eda2r 363R
Eda2r 160F
Eda2r 160R
Cre Tg F
Cre Tg R
Con F
Con R
Nkain1 F
Nkain1 R
IL11ra1 F
IL11ra1 R
BC037032 F
BC037032 R
Eda2r OT1F
Eda2r OT1R
Eda2r OT2F
Eda2r OT2R
Eda2r OT3F
Eda2r OT3R
Eda2r OT4F
Eda2r OT4R

Primer Sequence
TTACTAATATTGGCTTTTCTCAG
CCACAAAAGCCAACCTAAAGCAG
TTTACCTTCGAGAGCTCCTGTCCA1
AGCCACTACTTTAAAATCATTCTT1
GCGGTCTGGCAGTAAAAACTATC2
GTGAAACAGCATTGCTGTCACTT2
CTAGGCCACAGAATTGAAAGATCT2
GTAGGTGGAAATTCTAGCATCATCC2
CCCTGGGCAGCTGACATTTACATT
GTGGGTGGCTTCGGGTCAGTC
TTTGCCCACCCGCTACCTTACTT
CTGCCTTCTTCCCTCCCACACTC
TGGGTGTTGGGGTTGAGAAATGTT
GGCTCACGGCTAGGAATGGAAAG
TCTCCACTCCTGCCCTGACACC
GCCGTCCTAGCTTCCTGAGTATGT
GGTCTGGGTCTCTGGAATAAGTCG
AGCTGTACTGTGCCACCCTGAGAA
GCCAACGGGAATATCTGCGGTAGT
CTTCACATTGTGCAATGGGGTCTG
GGATAGCCGAGGGGATTGTCTGA
CTCCTCCCTCTGCTTTGGTGTGAC

Assay
PCR & Sanger of Eda2r
Genotyping: Eda2rΔ11
Genotyping: Alb-CreTg
Eda2r guide #1 off-target
Eda2r guide #1 off-target
Eda2r guide #1 off-target
Eda2r guide #1 off-target
Eda2r guide #1 off-target
Eda2r guide #1 off-target
Eda2r guide #1 off-target

1

The combination of these two primers will distinguish between Eda2r+/+, Eda2r Δ11/+,

and Eda2r Δ11/Δ11. Eda2r+ = 160 bp PCR product. Eda2rΔ11 = 149 bp PCR product. Must
resolve on a 4% agarose gel.
2

The combination of these four primers will distinguish between the presence and

absence of Alb-CreTg.
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5.3 Results
To generate knockout mice for Eda2r, a p53 target gene identified in our
transcriptomic analysis (see chapter 2) as commonly upregulated, wild-type C57BL6/J
zygotes were injected or electroporated with sgRNA targeting Eda2r (guide #1:
GAATGAGTACCGGGACCAATGGG

forward

strand

[score:

86];

guide

#2:

CACAGCGCCCCCATTGGTCCCGG reverse strand [score: 85]). Zygotes were then
implanted into pseudo-pregnant wild-type female mice. Pups obtained through
electroporation or injection of either guide were screened via PCR for on-target cutting
of Eda2r (forward primer: TTACTAATATTGGCTTTTCTCAG and reverse primer:
CCACAAAAGCCAACCTAAAGCAG, PCR product size; 363 base pairs [Table 8]). A
significant shift of the PCR project on an agarose gel and/or multiple product bands
signified the presence of on-target cutting. Of the 46 mice obtained, 5 mice resulted
from pronuclear injection of CRISPR guide #2, 17 resulted from electroporation of
CRISPR guide #1, and 24 from electroporation of CRISPR guide #2. Only 1 (20%) of
the 5 mice obtained through pronuclear injection had on-target cutting of Eda2r, the
other 4 mice were wild-type. From the 41 mice generated through guide
electroporation, 9 (21.95%) had on-target cutting. In total, the CRISPR guide cutting
efficiency, regardless of guide or technique used for delivery, was 21.74% (Figure 15).
To elucidate the exact alleles generated, we performed Sanger sequencing
around the CRISPR targeting site in exon 3, just downstream of the ATG site (Figure
16A) (Table 8). Since targeting occurred within close proximity to the ATG site,
generation of a knockout Eda2r allele from this method would only result in a maximum
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of 10 amino acids (25%) of the first tumor necrosis factor receptor domain of Eda2r
being translated (Figure 16B).
I deconvoluted the Eda2r knockout allele from four mice through Sanger
sequencing (Figure 16C). Two males, 2752 and 2753, were then selected for further
screening to determine if there was any off-target cutting from the CRISPR guides.
Both mice were selected because their Eda2r knockout alleles could be easily
resolved on an agarose gel, making them ideal candidates for future genotyping
strategies. 2752 had a 10 bp deletion (CCCCCATTGG) downstream of the ATG site
in exon 3, leading to a frameshift and premature stop after coding 114 bp. 2753 had
a 11 bp deletion (CCATTGGTCCC) downstream of the ATG site in exon 3, leading to
a frameshift and premature stop after coding 135 bp (Figure 16C). Both mice were
obtained through electroporation of guide #1.
These two mice were screened for 7 off-target sites through PCR amplification
followed by Sanger sequencing. Sites for evaluation were selected based on the score
given from crispr.mit.edu. We test at least 5 off-target sites, prioritizing those with the
highest scores. Also, any predicted off-target sites that fell on the same chromosome
as Eda2r (X chromosome) was profiled regardless of score (1/7 sites). 3 sites
contained an intact PAM sequence while 4 did not (Figure 17).
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Figure 15: CRISPR guide cutting efficiency for Eda2r KO mice
Pie charts for mice obtained through injection, electroporation, or both. Data analyzed
for on-target gene cutting through PCR amplification followed by resolution on an
agarose gel and/or Sanger sequencing of DNA around the targeting site.
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Figure 16: Eda2r knockout alleles generated using CRISPR technology
A: Schematic of the wild-type Eda2r gene. Numbered blue boxes denote exons. The
ATG site is in exon 3. B: Eda2r protein structure with amino acid numbers for domains
listed. TNFR = Tumor Necrosis Factor type I and type II receptors. TM =
Transmembrane domain. Green asterisk denotes CRISPR targeting site in both A&B.
C: Sequenced alleles generated with CRISPR.
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Figure 17: Off-target screening for Eda2r knockout mice 2752 and 2753
Schematic depicting results of Sanger sequencing for the top 7 off-target sites
predicted by crispr.mit.edu. Mismatches, indicated in purple, highlight the bases that
differ between the sgRNA and the potential off-target site.
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All 7 of the screened off-target sites were wild-type in both 2752 and 2753 mice.
However, to ensure absence of off-target cutting at sites that we did not test or could
not be predicted, these mice were backcrossed for two generations with a C57BL/6J
female mouse. We characterized only one Eda2r knockout allele. 2753 provided
offspring with germline transmission first, so I continued backcrossing this line of mice
for a total of two generations. (2752 was euthanized when 2753 achieved germline
transmission, but this does not indicate that germline transmission of the allele carried
by 2752 would not be possible). The Eda2r knockout allele will henceforth be referred
to as Eda2rΔ11 to reference the 11 bp deletion endured in founder mouse 2753.
Once backcrossing was completed, homozygous knockout mice, Eda2rΔ11/Y
and Eda2rΔ11/Δ11, were generated by crossing heterozygous female mice (Eda2rΔ11/+)
to either wildtype (Eda2r+/+) or hemizygous (Eda2rΔ11/Y) males. Eda2r knockout mice
were born at the expected mendelian ratio ([male: expected value (%): 23 (50%),
observed value (%): 24 (52.17%); c2 p-value = 0.087] and [[female: expected value
(%): 25.5 (50%), observed value (%): 24 (47.06%); c2 p-value = 0.389]). Three 30day-old male homozygous knockout mice were then euthanized, tissues were
collected, formalin-fixed, and H&E stained for histological analysis. The only tissue
with any distinct pathological differences observed was the liver (Figure 18).
Loss of Eda2r in mice resulted in vacuolation in the liver that was reminiscent
of liver-specific Mdm2 deletion (Mdm2FM/- Alb-CreTg or Mdm2FM/FM Alb-CreTg [FMAlb]).
The Alb-CreTg expresses Cre recombinase through the albumin promoter resulting in
liver-specific knockout of floxed alleles (Mdm2) (86). This model was previously
published by Kodama and colleagues in 2011 where they showed that liver-specific
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loss of Mdm2 results in spontaneous and p53-dependent fibrosis (87). Due to the
interesting similarities between these liver phenotypes, we generated a small cohort
of FMAlb mice in our lab so that we could directly compare livers between Eda2r Δ11
mice and FMAlb mice.
Upon in-house evaluation of these two models, vacuolation following loss of
Mdm2 is more centrilobular whilst Eda2r loss results in more diffuse and wide-spread
vacuolation. To further compare the Eda2rΔ11/Y and FMAlb models we conducted a
Chem8 panel on blood collected from these mice. Interestingly, both Eda2rΔ11/Y and
FMAlb mice had albumin, ALP, SGPT, SGOT, and creatinine levels outside of the
normal range (normal values provided by the MD Anderson Cancer Center
Department of Veterinary Medicine) (Table 9). However, it is important to note that
FMAlb livers were, on average, further from the normal range than Eda2rΔ11 livers
(additional blood panels are being conducted in order to determine if this difference is
statistically significant). To date, these comparisons have been made on 1-2-monthold Eda2rΔ11/Y and FMAlb male mice. However, preliminary data suggest that there is
no phenotypic difference between gender. Moreover, these cohorts of mice are still
aging but it does not seem that these liver phenotypes result in a significant decrease
in lifespan as we have both Eda2rΔ11 and FMAlb mice over 18 months-of-age currently
in our vivarium.
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Figure 18: H&E staining of Eda2rΔ11 livers
20X H&E images of livers from wildtype mice and mice that have germline loss of
Eda2r (Eda2rΔ11/Y) or liver-specific loss of Mdm2 (FMAlb; Mdm2FM/- Alb-CreTg) (all
males). Scale bar is 100 µm.
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Table 9: Chem8 blood panel of Eda2rΔ11 and FMAlb mice
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Due to the striking similarities between FMAlb and Eda2rΔ11 liver phenotypes,
we looked at p53 activation in these livers to determine if Eda2r is acting as a negative
regulator of p53 in this tissue. Loss of Eda2r correlated with elevation of p53 targets
Gtse1 and p21 (testing of additional p53 target genes is currently ongoing in these
mice) (Figure 19A). Surprisingly, the apoptotic p53 target gene Puma was repressed
(Figure 19A). This same expression pattern is seen in FMAlb mice, albeit to a higher
degree (FMAlb livers have approximately 10x higher expression of p21 and Eda2r
mRNA compared to Eda2rΔ11 livers) (Figure 19B). I speculate that Puma repression in
these mice is what is allowing them to form a liver when typically tissue-specific loss
of Mdm2 during development leads to an inability for proper organ formation (1).
Further studies would need to be conducted to support this claim. Eda2r mRNA was
also decreased, as expected, in Eda2rΔ11 livers (Figure 19A). However, the qRT-PCR
primers designed for this assay were not designed to discriminate between the
knockout allele and the wild-type allele hence there is still some amplification of Eda2r
mRNA in our knockout mice (Table 2).
Since p53 was transcriptionally activated in these livers we used
immunohistochemistry (IHC) to determine if there was also a detectable increase in
p53 protein levels. While FMAlb livers show strong p53 staining, p53 was undetectable
at the IHC level in livers lacking Eda2r (Figure 19C). Together, these data indicate
that germline loss of Eda2r results in liver defects that are similar to those seen
following loss of Mdm2. These defects correlate with p53 transcriptional activation
despite being unable to see increases in p53 protein levels. We are currently crossing
Eda2rΔ11 mice to p53-null mice to determine the p53-dependence of this phenotype.
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Figure 19: Loss of Eda2r is correlated with increased p53 transcriptional activity
but undetectable p53 protein
A&B: qRT-PCR results for Eda2rΔ11 (A) and Mdm2FM/FM Alb-CreTg (FMAlb) (B) liver
samples for p53 target genes. Control mice for (A) are littermates that are wildtype for
Eda2r. Control mice for (B) are either Mdm2FM/FM or Mdm2FM/- mice with no Cre allele
or mice with Alb-CreTg alone. All data presented as mean ± SD from individual mice.
Dots indicate biological replicates. Statistics performed using Student’s t test. C:
Immunohistochemistry (IHC) for p53 protein in wildtype, Eda2rΔ11, and FMAlb liver
sections.
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CHAPTER 6: NOVEL Gtse1 KNOCKOUT MICE HAVE DECREASED TESTES
SIZE RESULTING IN INFERTILITY
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6.1 Introduction
Our study, and others, have identified Gtse1 (G2 and S-phase expressed 1,
previously known as B99) as a downstream transcriptional target of p53 in multiple
cell types (2, 21, 88, 89). To further elucidate the role that this gene plays in the p53
pathway, we generated germline Gtse1 knockout mice.
Gtse1 is located on the positive strand of murine chromosome 15. The Gtse1
transcript is 16,786 base pairs spanning 12 exons. Gtse1 encodes a 741 amino acid
protein that is only expressed in the S and G2 phases of the cell cycle. In vitro studies
suggest that Gtse1 may be involved in p53 cell-cycle arrest, specifically at G2/M,
primarily by disrupting proper microtubule rearrangements (88, 89). However, these
studies are extremely limited. Additional in vivo studies are needed to elucidate the
role of Gtse1 within the p53 pathway.
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6.2 Methods
Gene targeting strategy
The ATG start codon is located within exon 1 of Gtse1. However, a guide with
a score >80 could not be found until exon 4, and thus the entire sequence of exon 4
was used to score possible target sites on the crispr.mit.edu webtool. Two guides with
high

scores

were

chosen

to

pursue

in

vivo

CCGGCGGTTTAAGTCCAAACTGG

reverse

strand

targeting
[score:

94];

(guide

#1:

guide

#2:

GACTTAAACCGCCGGGTTCCTGG forward strand [score: 95]). CRISPR sgRNA kits
were purchased from Synthego for each guide. The pronuclei of wild-type C57BL/6J
zygotes were then injected or electroporated with the sgRNA and Cas9 mRNA and
then implanted into pseudo-pregnant female mice ([Injection (guides injected
concurrently): sgRNA1: 400 nM, sgRNA2: 400 nM, Cas9 protein (Sigma, Enhanced
specificity): 200 nM, dilution buffer: 10 mM Tris pH 7.4, 0.1 mM EDTA] [Electroporation
(guides electroporated separately): sgRNA: 4 µM, Cas9 protein (Sigma, Enhanced
specificity): 4 µM, dilution buffer: Gibco Opti-mem [Thermo Fischer]). All injections and
electroporation of zygotes as well as implantation was performed by the MD Anderson
Cancer Center Genetically Engineered Mouse Facility (GEMF).

Animal Studies
Generation of Gtse1Δ7 mice is described in detail within this chapter.
Generation of these mice was performed in collaboration with the GEMF. Wildtype
C57BL/6J mice were initially purchased from the Jackson Laboratory (stock no:
000664). All mice were maintained in a >90% C57BL/6J genetic background.
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Genotyping was carried out as described earlier through PCR amplification followed
by resolution on an agarose gel (46).

Histopathology and immunohistochemistry
Tissues harvested from mice were fixed in 10% neutral buffered formalin or
Bouin’s fixative and paraffin-embedded. Tissue processing, paraffin embedding, 5
micrometer sectioning, and hematoxylin and eosin staining were performed on testes
fixed with Bouin’s by the MD Anderson Department of Veterinary Medicine and
Surgery Histology Laboratory. Immunohistochemistry was performed on samples
fixed in formalin using standard methods with citrate buffer or Tris-EDTA pH 9.0 for
30 minutes of antigen retrieval. Slides were stained with antibodies against p53 (CM5,
P53-CM5P-L, Leica Biosystems [dilution 1:200]), gH2AX (MA5-33062, ThermoFisher
Scientific [dilution 1:200]), and Sox9 (SAB4502834, Sigma-Aldrich [dilution 1:100]).
Visualization was performed using ABC and DAB kits (Vector Laboratories) and
hematoxylin was used as the counterstain. Slides were examined by light microscopy.

Quantitative real-time PCR (qRT-PCR)
RNA was extracted from frozen, pulverized murine tissues using Trizol reagent
(Invitrogen, Carlsbad, CA), and then reverse transcribed using iScript cDNA synthesis
kit (Biorad, Hercules, CA). qRT-PCR was carried out as previously described using
SYBR green (Bimake, Houston, TX) on the CFX384 Touch Real-Time PCR Detection
System (Biorad, Hercules, CA) (48). Expression was normalized to Rplp0.
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Statistical analyses
All data are presented as mean ± standard deviation (SD). All analyses were
performed using GraphPad Prism 8 software. p-value <0.05 were considered
significant. (*) p<0.05, (**) p<0.01 (***) p<0.001. Two groups were compared using a
Students t test and multiple groups were compared using ANOVA with Dunnett’s
correction for multiple comparisons.

Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.
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Table 10: Primer sets used for Sanger sequencing of Gtse1 knockout mice and
routine genotyping of the Gtse1Δ7
Primer Name
Gtse1 381F
Gtse1 381R
Gtse1 71F
Gtse1 71R
9530068E07RIKF
9530068E07RIKR
Gtse1 OT1F
Gtse1 OT1R
Gtse1 OT2F
Gtse1 OT2R
Gtse1 OT3F
Gtse1 OT3R
Gtse1 OT4F
Gtse1 OT4R

Primer Sequence
CGCAGCACAAATGAAGATGATGAA
GACATTCTGCCTGCCATCCTCG
CATAAAGAAAGATGCATTGCTGCC1
CCCGGGGCAAGAGGCTG1
TGGCAGCAGTGTTCCCTTTGA
GAACTCAGGCTGTCAGGGTAGGCA
CAGCCTGACATGCATTCCTCTAA
TGCAATGCCCTTAACCAAACTT
TCCGCACGTTCATGAGTTGTCTG
CACTCAGGCTCTTCCCCCAACC
GGTGGCCTTTCCTCCCTCCTG
GTGGTGGTGGTGGTGCTGTGAA
AGGTGTGGGGGTGGGGACTT
CCCATAGGACACAAAGGCTGAGG

Assay
PCR & Sanger of Gtse1
Gtse1Δ7 genotyping
Gtse1 guide #1 off-target
Gtse1 guide #1 off-target
Gtse1 guide #1 off-target
Gtse1 guide #1 off-target
Gtse1 guide #1 off-target

1

The combination of these two primers will distinguish between Gtse1+/+, Gtse1Δ7/+,

and Gtse1Δ7/ Δ7. Gtse1+ = 71 bp PCR product. Gtse1Δ7 = 64 bp PCR product. Must
resolve on a 4% agarose gel.
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6.3 Results
To generate knockout mice for Gtse1, a p53 target gene identified in our
transcriptomic analysis (see chapter 2) as commonly upregulated, wild-type C57BL6/J
zygotes were injected or electroporated with sgRNA targeting Gtse1 (guide #1:
CCGGCGGTTTAAGTCCAAACTGG

reverse

strand

[score:

94];

guide

#2:

GACTTAAACCGCCGGGTTCCTGG forward strand [score: 95]). Zygotes were then
implanted into pseudo-pregnant wild-type female mice. Pups obtained through
electroporation or injection of either guide were screened via PCR for on-target cutting
of Gtse1 (forward primer: CGCAGCACAAATGAAGATGATGAA and reverse primer:
GACATTCTGCCTGCCATCCTCG, PCR product size; 381 base pairs) (Table 10). A
significant shift of the PCR project on an agarose gel and/or multiple product bands
signified the presence of on-target cutting. Of the 126 mice obtained, 29 mice resulted
from pronuclear injection of CRISPR guide #1, 28 from injection of guide #2, 38
resulted from electroporation of CRISPR guide #1, and 31 from electroporation of
CRISPR guide #2. A small subset of mice (16/57 mice resulting from injection, 31/69
from electroporation, 47 mice total) were then profiled to determine on-target CRISPR
cutting. Of the 16 mice we profiled from the injection cohort, 4 (25%) had on-target
cutting at Gtse1. Additionally, 5 (16.13%) of mice we profiled from the electroporation
cohort had on-target cutting. In total, the CRISPR guide cutting efficiency of the mice
we profiled, regardless of guide or technique used for delivery, was 19.15% (Figure
20).
To elucidate the exact alleles generated, we performed Sanger sequencing
around the CRISPR targeting site in exon 4 (Figure 21A). Since the ATG site is in
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exon 1 of Gtse1 and we are targeting exon 4, the first ~50 amino acids of the protein
will be translated, corresponding to the first ~40 amino acids of the N-terminal domain
of Gtse1 (approximately one-third of this domain) (Figure 21A&B).
I deconvoluted the Gtse1 knockout allele from six mice through Sanger
sequencing (Figure 21C). Two males, 2622 and 2624, were then selected for further
screening to determine if there was any off-target cutting from the CRISPR guides.
Both mice were selected because their Gtse1 knockout alleles could be easily
resolved on an agarose gel, making them ideal candidates for future genotyping
strategies. 2622 had a 7 bp deletion (TGGACTT) downstream of the targeting site in
exon 4, leading to a frameshift and a premature stop after coding 150 base pairs
(Figure 21). 2624 had a 56 bp deletion with a subsequent insertion of 5 bp (CAAGC),
leading to a frameshift and a premature stop after coding a 162 bp sequence. Both
mice were obtained through electroporation of guide #1.
These two mice were screened for 5 additional off-target sites through PCR
amplification followed by Sanger sequencing. Since the original targeting guides used
to generate these mice had very high scores (94 and 95) these were the only 5
potential off-target sites predicted by crispr.mit.edu and thus all were screened. No
off-target sites fell on the same chromosome as Gtse1 (chromosome 15). 2 sites
contained an intact PAM sequence while 3 did not (Figure 22) (Table 10).
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Figure 20: CRISPR guide cutting efficiency for Gtse1 KO mice
Pie charts for mice obtained through injection, electroporation, or either. Data
analyzed for on-target gene cutting through PCR amplification followed by resolution
on an agarose gel and/or Sanger sequencing of DNA around the targeting site.
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Figure 21: Gtse1 knockout alleles generated using CRISPR technology
A: Schematic of the wild-type Gtse1 gene. Numbered yellow boxes denote exons. The
ATG site is in exon 1. B: Gtse1 protein structure with amino acid numbers for domains
listed. DUF = Domain of unknown function. Green asterisk denotes CRISPR targeting
site in both A&B. C: Sequenced alleles generated with CRISPR.
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Figure 22: Off-target screening for Gtse1 knockout mice 2622 and 2624
Schematic depicting results of Sanger sequencing for the top 5 off-target sites
predicted by crispr.mit.edu. Mismatches, indicated in purple, highlight the bases that
differ between the sgRNA and the potential off-target site.
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All 5 of the screened off-target sites were wild-type in both 2622 and 2624.
However, to ensure absence of off-target cutting at sites that we did not test or could
not be predicted, these mice were backcrossed for two generations with a C57BL/6J
female mouse. One Gtse1 knockout allele, from 2622, was characterized. It provided
offspring with germline transmission first, so these mice were backcrossed for two
generations. (2624 was euthanized when 2622 achieved germline transmission, but
this does not mean that germline transmission of the 2624 allele would not have been
possible). Thus, the Gtse1 knockout allele will henceforth be referred to as Gtse1Δ7 to
reference the 7 bp deletion in founder mouse 2622.
Once backcrossing was completed, homozygous knockout mice, Gtse1Δ7/Δ7,
were generated by crossing heterozygous mice together. Homozygous Gtse1
knockout mice were born at the expected mendelian ratio (expected value (%): 17.5
(25%), observed value (%): 19 (27.14%); c2 p-value = 0.1714). Three 60-day-old
homozygous knockout mice were then euthanized, tissues were collected, formalinfixed (testes fixed in Bouin’s and formalin), and H&E stained for histological analysis.
The only tissue with a robust morphological difference detected was the testes, which
lacked all major structures compared to heterozygous littermate control mice (Figure
23).
To gain insight into which cell types were altered due to Gtse1 loss, I performed
immunohistochemistry for presence of gH2AX and Sox9 protein in Gtse1Δ7/Δ7 testis
sections to detect spermatogonia and Sertoli cells, respectively (Figure 23) (90, 91).
Although further histological analysis is still needed, it appears that spermatogonia are
reduced by half and there are virtually zero detectable Sertoli cells in Gtse1Δ7/Δ7 testis
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compared to heterozygous littermate controls (Figure 23). Moreover, testes from
Gtse1Δ7/Δ7 mice were smaller than those of Gtse1Δ7/+ mice despite no differences in
age or body weight (Figure 24). In fact, these morphological defects seen in
homozygous Gtse1 knockout mice was severe enough that it renders all male
Gtse1Δ7/Δ7 mice infertile yet heterozygous males (Gtse1Δ7/+) bear normal litters (Figure
25).
To determine if these testicular defects were altering the p53 pathway
somehow, we assayed mRNA levels of downstream p53 target genes, Eda2r and p21,
in these homozygous knockout tissues as well as immunohistochemical staining for
p53 protein stabilization (Figure 26). To our surprise, there was neither strong
induction of these p53 target genes (only two have been tested to date) nor
stabilization of the p53 protein that could be captured with immunohistochemistry.
However, since infertility and decreased testes weight is a reported phenotype in mice
with elevated p53 levels (14), we think it is important to cross these mice to p53-null
mice to genetically test whether concomitant loss of p53 can restore fertility in
Gtse1Δ7/Δ7 males.

107

Figure 23: Morphological changes in Gtse1Δ7 testes
Top: 20X H&E images of testes from Gtse1Δ7/+ and Gtse1Δ7/Δ7 mice. Middle: 20X
images of immunohistochemical staining of gH2AX in testes from Gtse1Δ7/+ and
Gtse1Δ7/Δ7 mice. Bottom: 40X images of immunohistochemical staining of Sox9 in
testes from Gtse1Δ7/+ (section cut lengthwise, not crosswise) and Gtse1Δ7/Δ7 mice.
Scale bar is 100 µm.
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Figure 24: Gtse1Δ7 testes are substantially reduced in size.
A: Age, in days, of Gtse1Δ7/+ and Gtse1Δ7/Δ7 male mice analyzed. B: Body weight, in
grams, of Gtse1Δ7/+ and Gtse1Δ7/Δ7 male mice analyzed. C&D: Testes weight, in grams
(C) and as percent of body weight (D) for Gtse1Δ7/+ and Gtse1Δ7/Δ7 mice. Student’s t
test was utilized for statistical analysis. All data are presented as mean ± SD from
individual mice.
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Figure 25: Gtse1Δ7/Δ7 male mice are infertile.
A: The number of litters born in a six-month period from crosses with Gtse1 wild-type
(Gtse1+/+), heterozygous knockout (Gtse1d7/+), or homozygous knockout (Gtse1d7/d7)
males to Gtse1 wild-type females. B: The average litter size of litters born in (A).
Statistical analysis was conducted with ANOVA utilizing Dunnett’s test for multiple
comparisons against Gtse1 wild-type (+/+) mice. All data are presented as mean ± SD
from individual mice.
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Figure 26: Gtse1Δ7/Δ7 testes do not have higher p53 activation or protein
stabilization than Gtse1Δ7/+ littermates.
A&B: Relative mRNA level for Eda2r (A) and p21 (B) in Gtse1 heterozygous (d7/+) or
homozygous knockout (d7/d7) testes. All data are presented as mean ± SD from
individual mice. Differences are not significant when conducting a Student’s t test
against heterozygous (Gtse1d7/+) littermate controls. C: 40X images of p53
immunohistochemical staining in Gtse1 heterozygous (Gtse1d7/+) or homozygous
knockout (Gtse1d7/d7) testes.
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CHAPTER 7: LOSS OF p21 RESCUES INTESTINAL DEFECTS AND LETHALITY
RESULTING FROM ACTIVATION OF p53 IN ADULT MICE
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7.1 Introduction
We have previously reported that loss of Mdm2 is lethal in adult mice (2, 42).
Mdm2FM/- CAG-CreERTg (FMTg) mice present with multiple phenotypes with the most
robust being crypt dropout within the small intestines and non-cell-autonomous acinarto-ductal metaplasia (ADM) coupled with immune infiltration within the pancreas.
Importantly, none of these phenotypes are present within Mdm2+/- CAG-CreERTg (Tg)
control mice that retain Mdm2 after tamoxifen injections nor in FMTg mice that have
concomitant loss of p53 (Mdm2FM/- p53-/- CAG-CreERTg) signifying that these
pathologies are entirely p53-dependent (42).
However, the cause of death in FMTg mice and which p53 downstream target
genes are responsible for driving these phenotypes remains elusive. Here, we
knockout various p53 target genes, cell cycle arrest target gene p21 and apoptotic
target genes Puma and Eda2r, concurrently with Mdm2 loss to determine if these
genes are responsible for any pathologies observed in FMTg mice.
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7.2 Methods
Animal Studies
Mdm2FM, Mdm2+/-, and CAG-CreERTg mice have been described previously (2,
42). Puma-/- mice were provided by G. Zambetti (92). p21-/- mice were purchased
from the Jackson Laboratory (stock no: 003263) (93). Eda2rΔ11 mice were generated
within our lab and are described in chapter 7. Mice were maintained in >90% C57BL/6
background. Genotyping was carried out as described earlier through PCR
amplification followed by resolution on an agarose gel (46).
Tamoxifen treatments
Tamoxifen was purchased from Sigma-Aldrich. Tamoxifen was dissolved in
corn oil to be a final working concentration of 30 mg/mL. Once dissolved, Tamoxifen
was aliquoted into 500ul or 1mL aliquots to avoid freeze thaw cycles and stored at
-20° Celsius for up to 6 months while being continually protected from light. Mice were
subject to 3 daily doses of 1.5mg (3mg/40g; ~50ul) intraperitoneal (IP) tamoxifen.

Ventral Surface Temperature
Ventral surface temperature of live mice was taken using a non-contact infrared
thermometer designed for small rodents from Braintree Scientific, Inc. (IR-B153). The
thermometer has a 0.3-degree Celsius accuracy when reading between 25- to 40degrees Celsius. Temperature of each mouse was taken three times each day and
then averaged in order to increase confidence in thermometer accuracy. Thermometer
reading had to be stable for 3 seconds prior to being recorded.
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Histopathology and immunohistochemistry
Tissues harvested from mice were fixed in 10% neutral buffered formalin and
paraffin-embedded. Tissue processing, paraffin embedding, 5 micrometer sectioning,
and hematoxylin and eosin staining were performed by the MD Anderson Department
of Veterinary Medicine and Surgery Histology Laboratory. Immunohistochemistry was
performed using standard methods with citrate buffer or Tris-EDTA pH 9.0 for 30
minutes of antigen retrieval. Slides were stained with antibodies against p53 (CM5,
P53-CM5P-L, Leica Biosystems [dilution 1:200]), Lgr5 (ab75732, Abcam [dilution
1:50]), cytokeratin 19 (CK19) (ab133496, Abcam [dilution 1:5000]), and cleaved
caspase-3 (CC3) (9664, Cell Signaling [dilution 1:200]) Visualization was performed
using ABC and DAB kits (Vector Laboratories) and hematoxylin was used as the
counterstain. Slides were examined by light microscopy.

Quantitative real-time PCR (qRT-PCR)
RNA was extracted from frozen, pulverized murine tissues using Trizol reagent
(Invitrogen, Carlsbad, CA), and then reverse transcribed using iScript cDNA synthesis
kit (Biorad, Hercules, CA). qRT-PCR was carried out as previously described using
SYBR green (Bimake, Houston, TX) on the CFX384 Touch Real-Time PCR Detection
System (Biorad, Hercules, CA) (48). Expression was normalized to Rplp0.

Statistical analyses
All data are presented as mean ± standard deviation (SD). All analyses were
performed using GraphPad Prism 8 software. p-value <0.05 were considered
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significant. (*) p<0.05, (**) p<0.01 (***) p<0.001. Two groups were compared using a
Students t test and multiple groups were compared using ANOVA with Dunnett’s
correction for multiple comparisons. Survival curve comparisons were made using a
Log-rank Mantel-Cox test.

Study approval
All mouse studies were conducted in compliance with Institutional Animal Care
and Use Committee protocols.

116

Table 11: Primer sets used for genotyping the Rosa26-CreERT2, Puma-null, and
p21-null alleles
Primer
Name
oIMR8545
oIMR8546
oIMR8547
A1X
A2X
B6X
p21UP
p21+21A
neo18
1

The

Primer Sequence

Assay

AAAGTCGCTCTGAGTTGTTAT1
GGAGCGGGAGAAATGGATATG1
CCTGATCCTGGCAATTTCG1
TTATAGCCGGTGAGTCAGCAACG2
GCCTTCTTGACGAGTTCTTCTGAGG2
CCTGGAATTACAGGCAGTTGTCAGC2
GCTCCTGTGCGGAACAGGTCG3
AAGCCTTGATTCTGATGTGGGC3
GTCGATCAGGATGATCTGGACG3

combination of these three

primers

Genotyping: Rosa26CreERT2
Genotyping: Puma- allele
Genotyping: p21- allele

distinguish

between Rosa26+/+,

Rosa26CreERT2/+, and Rosa26CreERT2/CreERT2. Rosa26+ = 450 bp PCR product.
Rosa26CreERT2 = 600 bp PCR product.
The combination of these three primers distinguish between Puma+/+, Puma+/-, and

2

Puma-/-. Puma+ = 1 kb PCR product. Puma- = 300 bp PCR product.
The combination of these three primers distinguish between p21+/+, p21+/-, and p21-/-.

3

p21+ = ~750 bp PCR product. p21- = ~1kb PCR product.
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7.3 Results
Our lab, and others, have previously shown that loss of Mdm2 results in p53dependent lethality in adult mice (2, 42, 43). However, the cause of death and the p53
target genes contributing to this lethality, remains elusive. Here, we use the FMTg
(Mdm2FM/- CAG-CreERTg) model of genetic p53 activation in conjunction with the loss
of various downstream p53 target genes, to further elucidate the detrimental
phenotypes in these mice.
Following 3 daily 1.5 mg IP tamoxifen injections, FMTg mice become moribund
and lose ~15% of their body weight on average 4 days following the last tamoxifen
injection (Figure 27A) (Table 1). While Tg (Mdm2+/- CAG-CreERTg) control mice also
lose 5-10% of their weight immediately following tamoxifen injections, this weight is
regained quickly and Tg mice reach 100% of their starting weight in as little as 24
hours following the final injection (Figure 27A). In addition, FMTg mice see a rapid and
significant decrease in surface body temperature (Figure 27B). This hypothermia likely
signifies a wide-spread immune response as it has been previously reported that in
vivo treatment with lipopolysaccharide (LPS) induces an endotoxin-associated
immune response which ultimately manifests as impaired thermoregulation as quickly
as 90 minutes post treatment in rats (94, 95).
To further investigate if the hypothermia was a sign of infection, we collected
blood from Tg and FMTg mice via cardiac puncture and performed complete blood
counts. While most of the blood counts remained unchanged between the groups
(Figure 28), FMTg mice had an elevated white blood cell count with a significantly
higher portion of mature neutrophils, outside of the normal range (7.3-21.3% for 8-
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week C57BL/6J females and 11-33% for 8-week C57BL/6J males (96)), which is a
common sign of wide-spread sepsis (Figure 27C) (97-99).
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Figure 27: Loss of Mdm2 results in signs of severe GI toxicity in adult mice
A: Weight loss of Mdm2+/- CAG-CreERTg (Tg) and Mdm2FM/- CAG-CreERTg (FMTg)
mice following three daily 3mg/40g intraperitoneal tamoxifen injections administered
on days -2, -1, and 0 (denoted by yellow stars) presented as a percent of starting body
weight. A Student’s t-test was used for statistical analysis between groups on day 4.
Each line is an independent mouse. B: Ventral surface temperature between Tg and
FMTg mice on day 4. Taken with a non-contact infrared thermometer. Data are
presented as mean ± SD from individual mice. C: The number of white blood cells in
Tg and FMTg mice on day 4 and the percentage of said white blood cells that are
mature neutrophils collected from cardiac puncture. A Student’s t-test was used for
statistical analysis. Each dot represents an independent biological replicate. Data are
presented as mean ± SD. D: Representative hematoxylin and eosin (H&E) images of
the small intestine. Yellow lines denote healthy crypts. Scale bar: 100µm. E:
Immunohistochemical staining (IHC) for p53 in Tg and FMTg small intestines. Scale
bar: 100µm.
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Figure 28: Complete Blood Count with differential for Mdm2+/- CAG-CreERTg and
Mdm2FM/- CAG-CreERTg mice
A: Red blood cell, hemoglobin, hemocrit, mean corpuscular volume, mean corpuscular
hemoglobin, red cell distribution width, platelet, mean platelet volume, lymphocytes,
monocytes, eosinophils, and basophil blood cell counts for Mdm2+/- CAG-CreERTg
(Tg) and Mdm2FM/- CAG-CreERTg (FMTg) 2-month old mice. Blood was collected 4
days after IP tamoxifen injections. Data are presented as mean ± SD from individual
mice. A Student’s t-test was used for statistical analysis.
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To determine if loss of a downstream p53 target gene could dampen the
phenotypes or rescue the lethality seen when Mdm2 is lost in adult mice we crossed
FMTg mice to mice with germline loss of either p21, Puma, or Eda2r to generate the
following

experimental

cohorts:

Mdm2FM/-

Eda2rD11/ D11

CAG-CreERTg

(FMTg;Eda2r-/-), Mdm2FM/- Puma-/- CAG-CreERTg (FMTg;Puma-/-), and Mdm2FM/p21-/- CAG-CreERTg (FMTg;p21-/-) (Tables 1,8&10). Control mice for each cohort
were Mdm2 heterozygotes that contained the Cre transgene (Mdm2+/- CAG-CreERTg
(Tg), Mdm2+/- Eda2r-/- CAG-CreERTg, Mdm2+/- Puma-/- CAG-CreERTg, and Mdm2+/p21-/- CAG-CreERTg) and responded similarly to tamoxifen injections (Figure 29). In
fact, not only do these four control cohorts of mice have no differences in weight loss
following tamoxifen injections, none of these mice show alterations to their ventral
surface temperature, nor do they have any signs of p53-dependent intestinal defects
as measured by crypt dropout (Figure 29). Since there is no difference between
control mouse cohorts, all will be combined and displayed as Tg mice for the simplicity
of downstream analyses.

122

Figure 29: Biological response to tamoxifen injections amongst control mouse
cohorts
A: Mdm2+/- CAG-CreERTg (Tg), Mdm2+/- Eda2rD11/ D11 CAG-CreERTg (Tg;Eda2r-/-),
Mdm2+/- Puma-/- CAG-CreERTg (Tg;Puma-/-), and Mdm2+/- p21-/- CAG-CreERTg
(Tg;p21-/-) mouse weights following tamoxifen injections. Intraperitoneal tamoxifen
injections were administered on days -2, -1, and 0. Each line represents and individual
mouse with n=3 per genotype. Statistics on day 4 were done using ANOVA with
Dunnett’s correction for multiple comparisons to Tg mice. B: Ventral surface
temperature between various Tg mice on day 4. Taken with a non-contact infrared
thermometer. Data are presented as mean ± SD from individual mice. Statistical
analysis was performed using ANOVA with Dunnett’s correction for multiple
comparisons to Tg mice. C: H&E images of small intestine for all four control
genotypes. Images taken at 40X magnification. Scale bar is 100 µm. D: Quantification
of the number of healthy intestinal crypts within each genotype in 10, 40X fields of
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view. Statistical analysis was performed using ANOVA with Dunnett’s correction for
multiple comparisons to Tg mice. ns = not significant.
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All mice were administered 3 daily intraperitoneal (IP) tamoxifen injections of
1.5mg, monitored, and sacrificed when they became moribund (Figure 30A). FMTg,
FMTg;Puma-/-, and FMTg;Eda2r-/- mice all displayed signs of morbidity, on average,
4 days after the last tamoxifen injection and lost ~15% of their body weight (3 days
after tamoxifen injections when compared to their weight at the start of the experiment)
(Figure 30B). As expected, Tg mice that retain expression of Mdm2 do not become
moribund and display negligible weight loss as a result of the tamoxifen injections
(most Tg mice were at 100% of their starting weight four days after tamoxifen
injections) (Figure 30B). Surprisingly, FMTg;p21-/- mice display no sign of morbidity
even after being aged for 2 months (Figure 30A). While mice exhibited no morbidity,
FMTg;p21-/- mice lost some weight (~5% of their body weight) compared to Tg
controls but this is not significant.
Histologically, the rescue in lethality seen in FMTg;p21-/- mice correlates with
a complete rescue in the intestinal defects characterized in FMTg mice (Figure
30C&D). Not only was normal crypt structure completely restored in these mice but
the relative amount of Lgr5+ stem cells was comparable to controls despite this
population being significantly decreased in FMTg, FMTg;Eda2r-/-, and FMTg;Puma-/mice (moribund mice display about 25% less Lgr5+ stem cells compared to Tg and
FMTg;p21-/- mice) (Figure 30E&F). In addition to restoring normal intestinal
morphology, FMTg;p21-/- mice have normal pancreases (Figure 31A). FMTg;p21-/pancreases display no signs of cell death nor do they have increased cytokeratin 19
staining which marks the acinar-to-ductal metaplasia observed in FMTg mice (Figure
31).
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Figure 30: Concomitant loss of p21 rescues lethality and intestinal defects
resulting from Mdm2 loss in adult mice
A: Survival curves for Tg, Mdm2FM/- CAG-CreERTg (FMTg), Mdm2FM/- Eda2rD11/ D11
CAG-CreERTg (FMTg; Eda2r-/-), Mdm2 FM/- Puma-/- CAG-CreERTg (FMTg; Puma-/-),
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and Mdm2FM/- p21-/- CAG-CreERTg (FMTg; p21-/-) mice following 3 daily (3mg/40g)
tamoxifen injections. B: Weight of mice 4 days following tamoxifen injections
represented as a percent of their starting weight. Statistical analysis was performed
using ANOVA with Dunnett’s correction for multiple comparisons to Tg mice. ns = not
statistically significant. C: Hematoxylin and Eosin (H&E) staining of small intestines.
Yellow line denotes healthy crypt structures. Scale bar is 100 µm. D: Quantification of
crypt dropout presented as the number of healthy crypts present in 10 40X fields of
view. Statistical analysis was performed using ANOVA with Dunnett’s correction for
multiple

comparisons

to

Tg

mice.

ns

=

not

statistically

significant.

E:

Immunohistochemical (IHC) staining for Lgr5 in small intestine. Top five images are
at 40X with scale bar of 100 µm. Bottom five images are at 100X, focused on a single
crypt from the corresponding image above. Scale bar is 20 µm. Yellow arrows indicate
LGR5+ cells. F: Quantification of Lgr5+ cells presented as average percentage (%) of
crypts with Lgr5+ cells in 10 40X fields of view. Statistical analysis was performed
using ANOVA with Dunnett’s correction for multiple comparisons to Tg mice. ns = not
statistically significant. All data are presented as mean ± SD from individual mice.
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Figure 31: Concomitant loss of p21 rescues non-cell-autonomous metaplastic
phenotype in pancreases in FMTg mice
A: Hematoxylin and Eosin (H&E) [top], cleaved-caspase 3 (CC3) [middle], and
cytokeratin-19 (CK19) [bottom] staining of pancreases from Mdm2+/- CAG-CreERTg
(Tg), Mdm2FM/- CAG-CreERTg (FMTg), and Mdm2FM/- p21-/- CAG-CreERTg
(FMTg;p21-/-) mice. Scale bar is 100 µm. B&C: Quantification of CC3 (B) and CK19
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(C) staining represented in (A). Statistical analysis was conducted with ANOVA
utilizing Dunnett’s test for multiple comparisons against Tg mice. All data presented
as mean ± SD from individual mice. Dots indicate biological replicates.
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Currently, we are working towards understanding the mechanism by which p21
loss can completely alleviate the defects resulting from genetically elevated p53 in
vivo. My personal hypothesis is that, following p53 activation, p21 results in cell cycle
arrest of the intestinal stem cells. This renders these cells unable to repopulate the
gut following p53-dependent cell death of crypts and villi. While we are still exploring
this hypothesis through various experimental means, we have some in vivo data to
support this. Specifically, the Jackson Laboratories Mouse Genome Informatics (MGI)
database indicates that the Rosa26-CreERT2 allele results in markedly less
recombination in the small intestinal crypts compared to the CAG-CreERTg, as evident
by beta-galactosidase reporter activity (informatics.jax.org). These data suggest that
when Cre is driven by the Rosa26 locus different cell types, or an overall lower number
of cells, are targeted than when utilizing the CAG promoter despite reports that both
Cre alleles are expressed ubiquitously (54, 100). Thus, we tested whether a potential
decrease in recombination within intestinal crypts was sufficient to lessen the
morbidity seen in FMTg mice.
When utilizing the Rosa26-CreERT2 allele to drive Mdm2 loss (Mdm2FM/Rosa26-CreERT2 [FMRosa]) an average of 25% of cells within the entire small
intestine underwent recombination of the Mdm2FM allele when compared to mice
without the conditional Mdm2 allele ((Mdm2+/- Rosa26-CreERT2 [Rosa]) (Figure 32A)
(Tables 1&10). Similar results are achieved with the CAG-CreERTg allele in FMTg
mice (an average of 23% recombination) (Figure 32A). Rosa, Tg, FMRosa, and FMTg
mice all received 3 daily injections of 1.5 mg IP tamoxifen and recombination was
assayed 4 days after the last injection.
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Moreover, FMRosa mice successfully activated the p53 transcriptional program
in the small intestine, resulting in increased activation of our p53 signature described
in Moyer et al., 2020 (Figure 32B) (2). FMTg display much stronger activation of Gtse1
(relative mRNA level in FMTg = 10 and in FMRosa = 4), Polk (FMTg = 20, FMRosa
=2), and Zfp365 (FMTg = 10, FMRosa = 2) than FMRosa intestine yet the
consequences of these differences remain unknown (Figure 32B&C). Surprisingly,
despite comparable recombination (Figure 32A) and signs of p53 pathway activation
(Figure 32B), FMRosa mice do not become moribund following loss of Mdm2 while
FMTg mice survive only 4 days on average (Figure 32D). FMRosa survival is coupled
with a lack of robust crypt dropout in the small intestine (Figure 32E&F).
While we have yet to definitively show that the intestines are the cause of death
in FMTg mice, these studies begin to shed light on not only how ubiquitous Cre alleles
can result in surprisingly different in vivo phenotypes, but also how p53-dependent
cell-type specific pathologies are strongly correlated with lethality. More studies need
to be conducted targeting Mdm2 loss and subsequent p53 activation in a cell-typespecific manner in order to determine exactly what is driving these pathological
differences.
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Figure 32: Rosa26-CreERT2 mediated Mdm2 loss is unable to drive p53dependent lethality
A: Percent recombination of the Mdm2FM allele in the small intestine of FMTg
(Mdm2FM/- CAG-CreERTg) mice compared to Tg (Mdm2+/- CAG-CreERTg) and
FMRosa (Mdm2FM/- Rosa26-CreERT2) mice compared to Rosa (Mdm2+/- Rosa26CreERT2). Statistics were done using Student’s t test. B: qRT-PCR results presented
as relative mRNA levels of Tg, FMTg, Rosa, and FMRosa intestines for p53 signature
genes determined by Moyer et al (2). C: Correlation between the qRT-PCR results in
(B) for FMTg and FMRosa mice. R-squared and p-value are from a linear regression
test for goodness-of-fit. D: Kaplan-Meier survival curves for FMTg and FMRosa mice
following three daily injections of 3mg/40g tamoxifen with Log-rank (Mantel-Cox) test
for statistical analysis. E: H&E staining for Rosa and FMRosa small intestine. Yellow
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line depicts healthy crypts. Scale bar is 100 µm. F: Quantification of crypt drop out in
Tg, FMTg, Rosa, and FMRosa mice. Statistics were performed using ANOVA with
Dunnett’s correction for multiple comparisons. ns = not statistically significant. All data
are presented as mean ± SD from individual mice.
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CHAPTER 8: DISCUSSION AND FUTURE DIRECTIONS
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Discussion
An in vivo p53 transcriptional signature
The p53 transcription factor is responsible for orchestrating a cellular response
to all types of cell stress and thus, it is not surprising that it has the capability of
activating hundreds of genes in vivo (2, 101). However, the physiological
consequences of the promiscuous p53 transcriptional program, both on a tissue and
cell-specific level, had not been studied (11, 42). A greater understanding of wild-type
p53 function is warranted as the p53 pathway is altered in most, if not all, human
tumors (9). Understanding the genes responsible for p53 function in a given tissue
may lead to activation of specific downstream pathways and tumor suppression in
various cancers.
Our in vivo studies in mice employ a genetic model of p53 activation and have
provided crucial insight into the physiological p53 transcriptome. By conditionally
deleting the E3 ubiquitin ligase for p53, Mdm2 (FMTg mice, Mdm2FM/- CAG-CreERTg),
we examined p53 reactivation in 5 tissues, the murine pancreas, intestine, ovary,
kidney, and heart (compared to control Tg mice, Mdm2+/- CAG-CreERTg). We were
able to capture hundreds of tissue-specific and seven common p53 target genes by
comparing tissue-specific bulk RNA-sequencing data to existing ChIP-sequencing
data obtained from MEFs (21). While the majority of p53 target genes were
upregulated in our system, a small percentage of DEGs in the heart (6.3%), ovary
(4.8%), and pancreas (9.7%) were direct p53 targets and downregulated, implicating
an in vivo role for p53 repression. However, these genes were not independently
validated nor were any of them shared amongst the five sequenced tissues.
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The seven common differentially expressed genes identified – Ccng1, Eda2r,
Gtse1, Mdm2, Polk, Psrc1, Zfp365 – were validated both as p53 target genes at the
ChIP-qPCR level, and as readouts of p53 activity following radiation. This signature
validates the importance of the p53-Mdm2 feedback loop. Within 24 hours of loss of
Mdm2 from a cell, p53 initiated transcription of Mdm2 in attempts to regain balance
within the system.
Three of the seven genes identified are associated with p53 regulation of the
cell cycle, Ccng1, Gtse1, and Psrc1 (63-66). All tissues, except the heart, activated
pathways directly associated with the cell cycle suggesting that proliferative tissues
may have higher expression of cell cycle genes at the 24-hour time point compared
to tissues with lower turnover rates such as the heart. However, the overwhelming
prevalence of cell cycle genes in 4/5 tissues insinuates that the role of p53 in cell cycle
regulation may transcend cell and tissues types. p21, the first identified p53
transcriptional target which encodes a cell cycle inhibitor and driver of senescence
(102, 103), was differentially expressed only in FMTg pancreas, intestine, and kidney.
This suggests that it cannot be used as a universal read out for p53 activation.
Additionally, p21 is upregulated independently of p53 activity (104). More studies are
needed to understand exactly how the cell cycle is being perturbed. It is possible that
our analysis at the 24-hour timepoint after induction of p53 activity may have led us to
capture more p53-dependent cell-cycle genes. However, one should note that the
ability of p53 to arrest the cell cycle is an important tumor suppressive mechanism.
The other targets we identified highlight the importance of p53’s role following
DNA damage and in inducing cell death. Eda2r is suspected to be a p53 apoptotic
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target which, based on its ubiquity in our study, could be a more general method of
initiating cleaved-caspase dependent cell death as another apoptotic target Puma was
only differentially upregulated in FMTg kidney, intestine, and pancreas (62).
Polk is the gene that encodes DNA Polymerase Kappa which allows for DNA
replication in the presence of DNA lesions; DNA double strand breaks were observed
in all tissues and quantified by gH2AX staining as indicated above (Figure 6) (67, 68).
Additionally, Zfp365 is a zinc-finger protein required for proper resolution of DNA
double strand breaks; insinuating that p53 plays a ubiquitous role in the DNA-damage
repair response (69). Since Polk and Zfp365 expression are both reported to correlate
with DNA-damage, it is critical that the field explore DNA-damage repair as an
important mechanism of p53-mediated tumor suppression.
The fact that these seven genes were differentially expressed amongst multiple
different tissue types makes them a promising expression signature for wild-type p53
activity. Traditionally, the contribution of downstream p53 target genes to various
phenotypes (i.e. decreased Lif expression in uteri of p53-/- female mice contributes to
their reduced fertility) is often tissue-specific. However, our proposed signature
transcends these tissue-specific differences and provides ubiquity in an otherwise
promiscuous transcriptional program. We are currently exploring the use of this
signature as a biomarker for successful therapeutic p53 reactivation in cancers.
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Exploring the non-cell-autonomous nature of the p53 response within the pancreas
The juxtaposition of our ubiquitous CAG-CreER transgene data and acinar cellspecific Mist1-driven Cre exposed the non-cell-autonomous nature of the p53
response (73). Deletion of Mdm2 within the entire mouse resulted in a robust
metaplastic pancreas phenotype while acinar-cell specific Mdm2 loss driven by the
Mist1CreERT2 allele showed no signs of metaplasia. In fact, acinar-specific deletion of
Mdm2 resulted in no morphological differences within the pancreas.
Metaplasia develops as a response to inflammation or outside stress
suggesting that other tissues may be contributing to this pancreas phenotype (72).
Thus, we hypothesize that the concurrent intestinal defects may be releasing
endotoxins that cause a metaplastic pancreas (105, 106). In fact, one of the genes in
our signature, Eda2r, is a cell surface receptor suggesting a possible role in cell-cell
communication (82). Results such as these arise from studying the animal as an entire
system.

Transcriptional cell state changes driven by p53 within the small intestine
Single-cell RNA-sequencing data were generated to better understand the p53
pathway response at a single-cell level within a tissue. We utilized intestines for this
experiment since, within the 24hr time period after Mdm2 deletion, the intestine
displayed a remarkable crypt dropout phenotype and had the highest percentage of
differentially expressed genes with p53 binding sites (69%). Activation of p53 is
correlated with loss of multiple different cell populations in the murine intestine (distal
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enterocytes, memory CD4+ T cells, tuft, and goblet and paneth cells) which links nicely
with the robust cell death phenotype quantified by immunohistochemistry. The
mechanism by which these specific cell types are lost is still under exploration. The
significant decrease in relative proportion of these cells in FMTg mice compared to Tg
controls in just a 24-hour time period suggests that these cell types are more sensitive
to p53 activation than other intestinal cell types and may be more inclined to undergo
cell death, rather than cell cycle arrest, when experiencing damage/stress.
p53 also altered the transcriptional state of some intestinal cell populations.
Loss of Mdm2 increased a population of proximal enterocytes that are transcribing
oxidative phosphorylation genes thus potentially undergoing a metabolic shift in
response to p53 activation. This population of enterocytes has increased expression
of genes within oxidative phosphorylation pathways compared to other enterocyte
populations contained within Tg intestine. However, the total number of enterocytes
between Tg and FMTg mice was the same, indicating that this FMTg-specific cluster
of enterocytes is driven by p53-dependent transcriptional differences. Additionally, a
larger population of T cells was present in FMTg intestine that are upregulating cell
activation pathways implicating p53 in driving activation of intestinal T cells or that
activated T cells are being recruited to the FMTg intestine because of increased p53dependent cell death.
These studies have uncovered the physiological genes and pathways
regulated by p53 in vivo. A deeper understanding of how p53 responds on a cell- and
tissue-specific basis is important towards understanding its role in tumor suppression.
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Generation of novel knockout mice
Eda2r and Gtse1 are two of the seven genes that define our p53 transcriptional
signature and are involved in p53-dependent cell death and cell cycle arrest,
respectively (2, 21, 62, 63, 82, 88). However, both genes lacked robust in vivo studies
and thus I decided to generate germline knockout mice. Through electroporation of
CRISPR guides we were able to efficiently generate the Eda2rD11 and the Gtse1D7
knockout alleles.
Eda2rD11 displayed robust vacuolization within the liver that is reminiscent of
the pathologies resulting from liver-specific p53 activation driven by Mdm2 loss. This
vacuolization is correlated with an increase in p53 transcriptional activity though no
observable increase in p53 protein by immunohistochemical analysis. The striking
similarities between these two mouse models (Eda2rD11 and liver-specific Mdm2 loss)
suggests that Eda2r may be a negative regulator of p53 involved in a feedback loop
– much like Mdm2. While Eda2r mRNA levels are ubiquitously upregulated following
p53 activation, the liver-specific phenotypes seen in Eda2r knockout mice suggest that
Eda2r expression is indispensable for proper liver function and/or liver-specific p53
regulation. Further tissue-specific evaluation of Eda2r function is critical.
Gtse1D7 knockout male mice have a complete loss of normal testicular
morphology that is coupled with an overall decrease in testes size and weight
rendering these mice infertile. Infertility is often seen in mouse models with elevated
p53 activity and reports of in vitro experiments suggest that human GTSE-1 protein
can dampen p53 activity during the G2 and S-phase of the cell cycle when the GTSE1 protein is expressed (14, 63, 88). Together, these data suggest that Gtse1 may be
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acting as another negative regulator of p53. However, loss of Gtse1 in our knockout
mice does not increase p53 transcriptional activity (to date only Eda2r and p21 have
been tested) nor result in detectable p53 protein by immunohistochemistry. To
definitively and genetically test p53-dependence in this model, we are crossing p53null mice to our Gtse1 knockout mice. If Gtse1 is truly involved in a negative feedback
loop with p53, we would expect that Gtse1Δ7/Δ7 p53-/- males would have normal
testicular morphology and be fertile. Although Gtse1 is ubiquitously expressed
following p53 activation, it is not surprising that the reproductive system is more
sensitive to loss of a potential negative regulator of p53 as Mdm2 hypomorphic mouse
models have fertility defects resulting from elevated p53 despite other tissues
remaining functionally and morphologically normal (14).

Rescue of p53-dependent lethal phenotypes
Our group has been previously reported that loss of Mdm2 is lethal in adult
mice (2, 42). However, the cause of death in FMTg mice and which p53 downstream
target genes are responsible for driving these phenotypes remained elusive. By
crossing our FMTg model with mice harboring germline loss of either cell cycle arrest
target p21 or apoptotic targets Eda2r or Puma, we observed that lethality and
accompanying crypt dropout and metaplastic pancreas appear to be entirely
dependent on p21 activity. In fact, the proliferating cells of the intestine are found
exclusively within the crypt (107). During this “bottom-up” proliferation, the stem cells
divide and differentiate into the different necessary intestinal cell types as they move
out of the crypts and into the villi (108). However, following loss of stem cells within
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the crypt, the intestine switches from “bottom-up” to “top-down” proliferation; resulting
in dedifferentiation of the typically quiescent enterocytes to compensate for the loss
of cells in the crypts (109). Thus, we hypothesis that loss of p21 in our model is
allowing for increased cell proliferation, essentially speeding up the process of “topdown” compensation, protecting the crypts from excessive cell death. However, we
are still in the process of exploring this possibility in our model.
In addition to rescuing the lethal phenotype with concomitant deletion of p21,
we were able to mitigate the lethal pathologies that typically arise due to elevated p53
activity when by using the Rosa26-CreERT2 allele (100). Shockingly, the Rosa26CreERT2 allele did not cause lethality upon Mdm2 loss in adult mice while still losing
comparable amounts of Mdm2 throughout the intestine and activating p53
transcription as seen in the CAG-CreERTg mice. These results signify that intestinal
toxicity driven by p53 pathway activation is likely cell-type specific and that this cell
population in question, potentially the stem cells, is not targeted by the Rosa26CreERT2 allele. Another possibility is that the CAG-CreERTg allele results in more DNAdamage following Cre recombinase expression than does the Rosa26-CreERT2 allele.
The DNA-damage, coupled with elevated p53 activity due to loss of Mdm2, would
result in an overall increase in cell stress thus potentially swaying p53 to preferentially
activate cell death pathways – ultimately, causing lethality of the mice. Further
experimentation is requested to resolve the exact mechanism.
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Significance
Although p53 is highly studied, the molecular and physiological consequences
of the p53 transcriptional response are poorly understood. Through RNA-sequencing
of multiple mouse tissues upon genetic activation of p53, we identified hundreds of
tissue-specific p53 target genes and a set of genes which is commonly expressed and
can serve as a signature for p53 pathway activation. In the pancreas, we observed a
non-cell-autonomous

response

while

the small intestine

displayed

altered

transcriptional cell states. Our study begins to uncover the commonalities and
differences engrained in the tissue-specific and cell-specific p53 transcriptomes.
Gaining a better understanding of the wild-type p53 transcriptome will subsequently
lead to determining the elusive combination of genes responsible for the tumor
suppressive function of p53.

Future Directions
While the experiments derived from my thesis could potentially be taken in a
multitude of different directions, here I will briefly describe what I believe to be the
best next steps.

Eda2r as a potential negative regulator of p53
The striking similarities between Eda2rD11 knockout mice and liver-specific
Mdm2 loss (FMAlb) suggests that Eda2r may be a tissue-specific negative regulator
of p53. The liver is an interesting organ to work with because through simple tail-vein
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injections, a cDNA of interest can be delivered directly to the liver in vivo (110, 111).
Additionally, the liver is a naturally regenerative organ (112).
In order to address if Eda2r has the ability to dampen p53 activity in the liver,
one could use hydrodynamic injections to administer Eda2r and control cDNA to the
liver of Eda2r-knockout mice (Eda2rD11/D11 and Eda2rD11/Y). Then, following sufficient
time for liver regeneration, these tissues could be harvested for analysis. If Eda2r loss
was directly responsible for the increase in p53 activity and resulting phenotype then
following reintroduction of Eda2r cDNA we would expect to see not only a decrease
in the observed p53 transcriptional activation but also an alleviation of the increased
liver vacuolization.

Understanding the mechanism behind how loss of Gtse1 results in infertility
Gtse1D7/D7 males have decreased testis weight and function resulting in
complete infertility. While there is no gross morphological difference between ovaries
of Gtse1D7/+ and Gtse1D7/D7 females, H&E staining of ovary sections should be obtained
and thoroughly inspected by a pathologist. Additionally, Gtse1D7/+ and Gtse1D7/D7
female mice should be mated with wild-type C57BL/6J male mice to determine if
complete loss of Gtse1 decreases fertility in females. If the infertility resulting from
Gtse1 loss is gender-biased then we will be able to narrow down where the defect is
originating from – whether it be a meiotic defect that both genders are vulnerable to
or if something unique to the testes, and/or testicular development, relies on Gtse1
expression for proper function.
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Cell-type specific loss of Mdm2 to address p53-dependent GI toxicities
We have sufficient in vivo data to suggest that p53 activation in the crypts of
mice likely results in p53-dependent cell-cycle arrest through activation of p21. I
speculate that this arrest is blocking the intestines ability to undergo compensatory
proliferation, resulting in crypt dropout and ultimately death of FMTg mice.
The intestine has a resident stem cell population which resides in the crypts
and express Lgr5 (113). In order to address whether these crypt/stem cell-specific
alterations are resulting in lethality, I propose we utilize the Lgr5-CreERT2 allele to
drive loss of Mdm2 specifically within Lgr5+ stem cells (114). If my hypothesis is
correct, we would suspect that p53 activation in the intestinal stem cells alone
(Mdm2FM/- Lgr5-CreERT2 [FMLgr5]) will result in lethality of adult mice. We could then
cross these FMLgr5 mice to the p21 germline knockouts to verify that p21 still rescues
these intestine-specific defects.
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APPENDIX
Appendix A: Simplified R-Script used for single-cell sequencing analysis with
Seurat V3 package
Below is a simplified version of the R-Script generated during analysis of FMTg
and Tg single-cell RNA-sequencing data generated from the intestine (Chapter 4).
Additional commands and plots were performed/generated but are not included here
to avoid confusion. R-Script starts following downloading of two separate datasets
(FMTg and Tg) to combine into one Seurat object (Combo) for downstream analysis.
Before combining the two datasets, a column entitled “orig.ident” was added to each
dataset with either FMTg or Tg (depending on genotype) so that once combined, the
data could be sorted based on the original mouse it was generated from. This script
is not written to be copy and pasted into R but can serve as a starting point for those
analyzing similar single-cell RNA data sets. Cross-validation of the script and use of
the tutorials on the Seurat website (Satijalab.org/Seurat) is vehemently encouraged
for they were invaluable to this analysis (75-77, 79).

> library(dplyr)
> library(Seurat)
> library(patchwork)
> #load your datasets from wherever they are stored with the Read10X command
>#in this example code, datasets were saved to my personal desktop
> FMTg.data <Read10X(“/Users/smoyer/Desktop/scRNA/SC26_FMTG/filtered_feature_bc_matrix”)
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> Tg.data <Read10X(“/Users/smoyer/Desktop/scRNA/SC26_TG/filtered_feature_bc_matrix”)
> #generate Seurat objects with the non-normalized data for the project which I
named “scGI”
> FMTg <- CreateSeuratObject(counts = FMTg.data, project “scGI”, min.cells = 3,
min.features = 200)
> FMTg[[“orig.ident”]] <- (“FMTg”)
> Tg <- CreateSeuratObject(counts = Tg.data, project “scGI”, min.cells = 3,
min.features = 200)
> Tg[[“orig.ident”]] <- (“Tg”)
> #Transform the datasets
> FMTg = SCTransform(FMTg)
> Tg = SCTransform(Tg)
> #Combine the two datasets which will now be called Combo
> Combo <- merge(x= FMTg, y = Tg)
> Combo <- ScaleData(Combo, verbose = FALSE)
> #generate a column in the dataset that will contain all mitochondrial genes
> #use “^MT-“ if you are analyzing a human dataset
> Combo[[“percent.mt”]] <- PercentageFeatureSet(Combo, pattern = “^mt-“)
> #visualize the QC metrics as a violin plot
> VlnPlot(Combo, features = c(“nFeature_RNA”, “nCount_RNA”, “percent.mt”), ncol
= 3)
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> Plot1 <- FeatureScatter(Combo, feature1 = “nCount_RNA”, feature2 =
“percent.mt”)
> Plot2 <- FeatureScatter(Combo, feature1 = “nCount_RNA”, feature2 =
“nFeature_RNA”)
> Plot1 + Plot2
> #generate a subset of the large dataset that will include the cells that you have
decided pass QC based on violin plots
> Combo <- subset(Combo, subset = nFeature_RNA > 200 & nFeature_RNA < 6500
& percent.mt < 30)
> #default normalization will be a log-transform with a scale factor of 10,000
> Combo <- NormalizeData(Combo)
> Combo <- FindVariableFeatures(Combo, selection.method = “vst”, nfeatures =
2000)
> #Identify the 10 most highly variable genes
> top10 <- head(VariableFeatures(Combo), 10)
> #plot variable features with and without labels
> Plot1 <- VariableFeaturesPlot(Combo)
> Plot2 <- LabelPoints(plot = Plot1, points = top10, repel = TRUE)
> Plot1 + Plot2
> #perform linear dimensional reduction
> #this will use the previously generated subset as default input
> Combo <- RunPCA(Combo, features = VariableFeatures(object = Combo))
>print(Combo[[“pca”]], dims = 1:5, nfeatures = 5)
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>VizDimLoadings(Combo, dims = 1:2, reduction = “pca”)
>DimPlot(Combo, reduction = “pca”)
> DimHeatMap(Combo, dims = 1, cells = 500, balanced = TRUE)
> DimHeatMap(Combo, dims = 1:15, cells = 500, balanced = TRUE)
> #determine dimensionality
> #visualization tools for comparing the p-values for each PC
> #significant PCs will be used for downstream analysis
> Combo <- JackStraw(Combo, num.replicate = 100)
> Combo <- ScoreJackStraw(Combo, dims = 1:20)
> JackStrawPlot(Combo, dims = 1:15)
> ElbowPlot(Combo)
> Combo <- FindNeighbors(Combo, dims = 1:8)
> Combo <- FindClusters(Combo, resolution = 0.5)
> #Look at cluster IDs for the first 5 cells
> head(Idents(Combo), 5)
> #run non-linear dimensional reduction (UMAP/tSNE)
> #use the same PCs as input as you did for above clustering analysis
> #for me that is 8 PCs
> Combo <- RunUMAP(Combo, dims = 1:8)
> DimPlot(Combo, reduction = “umap”)
> p1 <- DimPlot(Combo, reduction = “umap”, group.by = “orig.ident”)
> p2 <- DimPlot(Combo, reduction = “umap”, label = TRUE)
> p1 + p2
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> DimPlot(Combo, reduction = “umap”, split.by = “orig.ident”)
> #find differentially expressed features
> #min.pct requires a feature to be detected at a minimum percentage of 25
> cluster2.markers <- FindMarkers(Combo, ident.1 = 2, min.pct = 0.25)
> head(cluster2.markers, n = 10)
> cluster5.markers <- FindMarkers(Combo, ident.1 = 5, min.pct = 0.25)
> head(cluster5.markers, n = 10)
> #change n value to whatever you would like
> cluster4.markers <- FindMarkers(Combo, ident.1 = 4, min.pct = 0.25)
> head(cluster4.markers, n = 10)
> #Find all markers distinguishing cluster 2 from clusters 0 and 10
> cluster2.markers.distinguish <- FindMarkers(Combo, ident.1 = 2, ident.2 = c(0,10),
min.pct = 0.25)
> head(cluster2.markers.distinguish, n = 25)
> #Find all markers distinguishing cluster 5 from cluster 7
> cluster5.markers.distinguish <- FindMarkers(Combo, ident.1 = 5, ident.2 = 7,
min.pct = 0.25)
> head(cluster5.markers.distinguish, n = 25)
> #Find all markers distinguishing cluster 4 from clusters 6 and 13
> cluster4.markers.distinguish <- FindMarkers(Combo, ident.1 = 4, ident.2 = c(6, 3),
min.pct = 0.25)
> head(cluster4.markers.distinguish, n = 25)
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> #Find all markers for every cluster comparted to all remained cells, report only the
postivie ones
> Combo.markers <- FindAllMarkers(Combo, only.pos = TRUE, min.pct = 0.25,
logfc.threshold = 0.25)
> #This will take a few minutes to run
> Combo.markers %>% group_by(cluster) %>% top_n(n=3, wt = avg_logFC)
> View(Combo.markers %>% group_by(clusters) %>% top_n(n = 3, wt =
avg_logFC))
> #Generate violin plots to see where cell-type defining genes are expressed.
> #some examples are below but you can do this for seemingly any gene of interest
> VlnPlot(Combo, features = “Cd3d”)
> VlnPlot(Combo, features = “Lgr5”)
> VlnPlot(Combo, features = “Ms4a1”)
> VlnPlot(Combo, features = “Cd8a”)
> #Split violin plots to determine if one genotype is expressing said gene of interest
more than the other
> #instead of violins you can use FeaturePlot to generate colored UMAPs that color
gene of interest across UMAP
> #instead of violins you can use DoHeatmap to generate an expression heatmap
for gene of interest across clusters
> #some examples are below but you can do this for seemingly any gene of interest
> VlnPlot(Combo, features = “Muc2”, split.by = “orig.ident”)
> VlnPlot(Combo, features = "Mdm2", split.by = "orig.ident")
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> VlnPlot(Combo, features = "Bub3", split.by = "orig.ident")
> VlnPlot(Combo, features = "Vav1", split.by = "orig.ident")
> #Look at multiple genes on one violin plot
> #For example, you could look at all genes associated with a specific cell type
> #You can also split these by the original identity
> #You could look at the p53 signature generated in my PNAS paper and then split
by orig.ident to see that these genes are expressed in FMTg cells and not Tg
> #Example below
> VlnPlot(Combo, features = "Chgb", "Gfra3", "Cck", "Vwa5b2", "Neurod1") split.by =
"orig.ident")
> #generation of a dot plot for p53 signature genes split by the original identity
> degs.to.plot <- c("Eda2r", "Gtse1", "Polk", "Psrc1", "Zfp365", "Mdm2", "Ccng1")
> DotPlot(Combo, features = rev(degs.to.plot), cols = c("blue", "red"), dot.scale = 8,
split.by = "orig.ident") + RotatedAxis()
> #Save script along the way
> #Look at every gene that interests you
> #Remember to export plots and table from R studio
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